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ABSTRACT 
 Acute lower respiratory tract infections are a persistent and pervasive 
public health burden, often caused by Streptococcus pneumoniae. 
Hospitalization rates due to pneumonia fall dramatically during early childhood, 
remain low during early adult years, and then increase steadily around middle 
age. The low-susceptibility period of early adulthood is likely due to frequent 
respiratory exposures to diverse pneumococcal serotypes resulting in serotype-
independent heterotypic immunity. We hypothesize that resolution of repeated 
respiratory pneumococcal infections establish capsule-independent, lung-
resident adaptive immunity that protects against subsequent unrelated 
pneumococcal pneumonia. In our model of naturally acquired heterotypic 
immunity, mice are infected with diverse serotypes of pneumococci in the 
respiratory tract, given time to recover, and then challenged by pulmonary 
infection with a highly virulent serotype 3 pneumococcus (Sp3). Prior exposures 
to unrelated pneumococci resulted in multi-log reductions in Sp3 bacterial lung 
burdens and long-term sterilizing immunity. The enhanced lung defense during 
pneumonia included more Th17 cells in the lung and significantly elevated IL-17A 
  x 
as well as neutrophils in the airspaces. Depletion of CD4+ cells resulted in less 
effective antibacterial defense. Upon ex vivo stimulation with pneumococcus 
lung-resident CD4+ cells produced multiple protective cytokines including IL-17A, 
IFN-γ, IL-22, IL-2, and TNF-α. In protected lungs, there were increased numbers 
of CD4+ resident memory T (TRM) cells, confined to the anatomic region of the 
initial infections. Heterotypic protection was also confined to the site of previous 
pneumococcal infections. Previously-exposed mice challenged in their 
contralateral lobes were not protected. RNAseq analysis of heterotypic lungs 24h 
after Sp3 infection revealed an enrichment of lymphocyte-related pathways 
including immunoglobulin and other B cell-related genes. B cell-deficient µMT-/- 
mice exposed to pneumococci had intermediate protection against Sp3 
pneumonia, better than naïve mice but less effective than fully immunocompetent 
peers. Plasma from mice previously exposed to pneumococci was sufficient to 
protect naïve mice against Sp3 pneumonia. We conclude that mechanisms of 
naturally-acquired heterotypic protection against pneumococcus involve both 
lung-resident cell-mediated and humoral immunity and importantly this protection 
can be compartmentalized within the lung. Advancing our understanding of these 
mechanisms will guide future vaccine development and treatment strategies for 
lung disease.  
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CHAPTER ONE: INTRODUCTION 
Pneumonia 
History and clinical significance 
 Pneumonia has long been regarded as one of the most important 
diseases of the modern era. In the early 1900s William Osler described 
pneumonia as “one of the most widespread and fatal of all acute diseases-the 
Captain of the Men of Death” (Osler, 1909). In the United States in the early 20th 
century deaths due to pneumonia rose from 90.6 per 1,000 in 1890 to 106.1 per 
1,000 in 1900 with a noted increase in large cities like New York and Chicago 
(Osler, 1909). The overall fatality rate at this time was estimated to be between 
30 and 40% (Ratner and Weiser, 2006). Some experts even suggest that the 
majority of deaths during the 1918-1919 influenza pandemic were as a result of 
complicating secondary bacterial pneumonia (Fedson, 2009; Morens et al., 
2008). Common clinical symptoms of community-acquired pneumonia included 
dry cough, fever, chills, dyspnea, and pleuritic chest pain (Blasi et al., 2007; 
Singer et al., 2008).  
Prior to the widespread use of antibiotics, serotherapy was used to treat 
patients with pneumonia. This treatment involved the infusion of immune serum 
from previously inoculated animals into patients with active disease (Watson et 
al., 1993). During the early stages of serum therapy for pneumonia the results 
were mixed, because the concept of immunologically distinct bacterial “types” 
within a species was not fully understood (Podolsky, 2005). Type-specific serum 
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greatly improved the efficacy of the therapy in the 1920s, but it was still labor 
intensive, costly, and hospital dependent due to the risk of serum sickness 
(Podolsky, 2005). With the discovery of an increasing number of bacterial 
serotypes that required type-specific serum therapy it became clear that this 
therapy option was not sustainable.  
In the early 1930s serum therapy was replaced by broadly-targeting 
antimicrobial compounds that revolutionized the management and treatment of 
once incurable bacterial infections. The first chemotherapeutic compound that 
effectively treated bacterial pneumonia was sulfapyridine (Singer et al., 2008; 
Watson et al., 1993). One study in England reported that sulfapyridine treatment 
reduced the overall fatality rate in pneumonia patients from 27% to 8% (Watson 
et al., 1993). By the end of World War II however, sulfapyridine-resistant strains 
of bacteria emerged and the drug was phased out by the less toxic, more 
effective antibiotic penicillin (Podolsky, 2005; Watson et al., 1993). In the 
decades following the war antibiotic overuse contributed to increasing antibiotic 
resistance (Podolsky, 2005). 
Pneumonia remains a significant global public health burden today. From 
1990 to 2002 the WHO consistently ranked lung infections as the highest global 
burden of selected diseases measured by disability-adjusted life years lost 
(DALYs) above both HIV/AIDS and neoplasms (Mizgerd, 2006). Poorer 
populations are especially at risk for acute lower respiratory tract infections due 
to socioeconomic issues like sanitation, nutrition, hygiene, education, and access 
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to healthcare (Mizgerd, 2012). In fact, people living in poverty see a 20-fold 
increase in the relative burden of lung infections (Mizgerd, 2006). In the United 
States pneumonia was the most common reason for the hospitalization of 
children in 2009 (Yu et al., 2006) and accounted for nearly half of the infectious 
disease-related hospitalizations and deaths of older adults from 2000-2002 
(Curns et al., 2005). Pneumonia disproportionally affects the very young and very 
old with differential underlying immunological explanations (Quinton and Mizgerd, 
2015). Data collected from 1970 to 1996 shows that there was little to no 
progress in reducing mortality due to pneumonia and influenza in the United 
States (Armstrong et al., 1999).  
 
Causes of Pneumonia 
 Pneumonia is a heterogeneous disease that has varied etiology including 
bacterial, viral, and less commonly fungal (Jones, 2010; Musher and Thorner, 
2014). It is useful when discussing the etiology of pneumonia to make the 
distinction between community-acquired (CAP) and hospital-acquired pneumonia 
(HAP). As the name implies, CAP is an acute lung infection that was acquired in 
the community or a non-health care setting (Musher and Thorner, 2014; Steel et 
al., 2013). If a patient develops an acute lung infection or pneumonia > 48 hours 
after hospital admission it is considered HAP (Jones, 2010). CAP is most often 
caused by bacteria with Streptococcus pneumoniae (pneumococcus) at the top 
of the list of bacterial pathogens. Sources vary regarding the prevalence of 
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pneumococcal pneumonia, some studies state that 10-15% (File et al., 2010; 
Musher and Thorner, 2014) of pneumonia cases are caused by pneumococcus 
while others claim 30-50% (Igor Rudan, 2008; Shann, 1986). The reason for this 
lack of consensus could be due to other factors complicating the integration of 
data from multiple studies such as the age of the patients studied, geographic 
location, method of diagnostic test and pneumococcal vaccination (discussed 
later). Other bacterial causes of CAP include Haemophilus influenzae and 
Moraxella catarrhalis, as well as atypical pathogens like Mycoplasma 
pneumoniae, Chlamydophila pneumoniae, and Legionella species (Garau and 
Calbo, 2008). HAP is more commonly caused by Staphylococcus aureus and the 
gram negative bacteria such as Pseudomonas aeruginosa, Enterobacter 
species, Klebsiella species, and Escherichia coli (Jones, 2010). 
Following the development of the polymerase chain reaction (PCR) and its 
subsequent usage for diagnostic purposes it has become increasingly clear that 
viral pathogens also play an important role in acute lung infection. Studies of 
childhood pneumonia patients in developing countries have shown that 
respiratory syncytial virus (RSV) can be detected in 15-40% of hospital 
admissions (Igor Rudan, 2008). These studies also detected influenza A and B, 
parainfluenza, human metapneumovirus and adenovirus but with less frequency 
(Igor Rudan, 2008; Stensballe et al., 2003; Weber et al., 1998). A study of 
pneumonia cases requiring hospitalization among U.S. adults published in 2015 
found that the most common pathogen detected was human rhinovirus (9% of 
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cases) followed by influenza virus (6%), and S. pneumoniae (5%) (Jain et al., 
2015). It should be noted however that in the majority of patient samples (62%) a 
pathogen was not detected making a firm determination of etiology in this cohort 
difficult. While the data vary on the ability of viral pathogens to cause severe 
pneumonia, studies show that the risk of secondary bacterial pneumonia is 
increased in children in developing countries following a primary infection with 
RSV (Forgie et al., 1991; Garau and Calbo, 2008).  
Certain comorbidities can be associated with an overall risk of developing 
pneumonia and more specifically with which pathogen causes disease. Some 
examples of comorbid risk factors for CAP include chronic cardiorespiratory 
diseases, chronic renal disorders, diabetes, hepatic conditions, cancer, and HIV 
infection (Steel et al., 2013). In countries with higher rates of HIV infection, 
bacterial pneumonia is a significant cause of mortality in addition to infections 
caused by other pathogens such as Pneumocystis jiroveci (Igor Rudan, 2008; 
Steel et al., 2013). Additionally, chronic obstructive pulmonary disease (COPD) is 
associated with a higher risk of CAP caused by H. influenzae and M. catarrhalis 
as well as by gram negative bacteria such as Pseudomonas aeruginosa (Mandell 
et al., 2007; Musher and Thorner, 2014). Elderly pneumonia patients over the 
age of 80 typically with at least one complicating health condition are more likely 
to have a poor prognosis and longer recovery times with the possibility of full 
recovery never being achieved (Marrie, 2000).  
 
  
6 
The Pneumococcus 
 Streptococcus pneumoniae, pneumococcus, is a gram positive, lancet-
shaped, facultative anaerobic bacterium that is observed singularly, as 
diplococci, or in short chains (CDC, 2015). Pathogenic qualities of this organism 
were first described in 1881 simultaneously by two microbiologists, George M. 
Sternberg in the United States and Louis Pasteur in France (Watson et al., 
1993). Both researchers demonstrated the pathogenic capacity of pneumococci 
from human saliva in animal models (Watson et al., 1993). Pneumococcus was 
so named in the late 19th century by Fraenkel due to its tendency to cause 
respiratory disease (Watson et al., 1993). Before the discovery and widespread 
use of antibiotics, pneumococcus was a main target of passive serum therapy for 
acute lung infections. During the era of serum therapy it became apparent that 
antiserum was protective against a homologous infection (infection with the same 
organism), but in other patients with pneumococcal pneumonia antiserum 
provided little help (Austrian, 1999). This clinical observation and others 
regarding the microscopic appearance and differential behavior of different 
pneumococcal clinical isolates during agglutination reactions led to the discovery 
of distinct pneumococcal types (Austrian, 1999).  
 The outermost surface of the pneumococcus is a layer of complex 
polysaccharides that make up the capsule, which in most cases is covalently 
attached to the bacteria cell wall (Geno et al., 2015). Pneumococcal capsular 
types have distinct biochemical properties that are determined by the 
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composition and linkages of the oligosaccharide chains (Geno et al., 2015; 
Kadioglu et al., 2008). Pneumococcal isolates with unique polysaccharide 
chemical structures that have distinct immunologic properties are grouped into 
serotypes. The heterogeneity of capsular polysaccharides is evident, as today 
more than 90 pneumococcal serotypes have been identified (Bogaert et al., 
2004; Bridy-Pappas et al., 2005; Henriques-Normark and Tuomanen, 2013; 
Kadioglu et al., 2008). The quellung reaction, first developed in the early 1900s 
by Neufeld, remains the gold standard for typing pneumococcal isolates and is 
also used for identifying and typing other capsule-producing bacteria (Austrian, 
1999; Habib et al., 2014). The method involves observing antigen-antibody 
interactions when pure pneumococcal suspensions are combined with pooled 
and specific antisera directed against the polysaccharide capsule (PC) (Habib et 
al., 2014). When a type-specific serum binds to the PC of the pneumococcal 
isolate being tested, its refractive index changes and the bacteria appear as 
swollen and more visible when viewed under a microscope; this is a positive 
quellung reaction (Habib et al., 2014).  
 In addition to determining the distinct serotypes of pneumococcus, the PC 
is also a major virulence factor (Bridy-Pappas et al., 2005). The PC of 
pneumococcus is known to disrupt an essential host protective mechanism, 
opsonin-dependent phagocytosis, both complement and antibody-mediated 
(Bogaert et al., 2004; Hammerschmidt et al., 2005). The capsule creates a steric 
hindrance and prevents leukocytes from accessing complement that may be 
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fixed on the surface of the bacteria, and thus serotypes that produce more PC 
are likely to be more virulent (Bridy-Pappas et al., 2005). In addition to 
pneumonia, pneumococcus also causes otitis media and other invasive diseases 
like meningitis and sepsis. The capsule plays a vital role during nasopharyngeal 
colonization (essential for disease development), invasion of the epithelial 
barrier, and spread from the respiratory tract (van der Poll and Opal, 2009). The 
importance of the PC in the virulence of pneumococcus is evidenced by the fact 
that it is the target of current vaccine strategies. 
The genes encoding the PC of pneumococcus are located in a single 
locus in a cassette arrangement and are flanked by conserved common genes 
involved in capsule regulation (Geno et al., 2015). Because pneumococci are 
naturally competent and able to take up DNA, their genomes can be highly 
variable. The exchange of genetic material between pneumococci facilitates the 
spread of antibiotic resistance and capsule switching resulting in a high degree of 
diversity (Henriques-Normark and Tuomanen, 2013; Kalin, 1998). Other 
virulence factors include but are not limited to the cytotoxin pneumolysin, and the 
cell wall components pneumococcal surface protein A (PspA), pneumococcal 
surface protein C (PspC), and pneumococcal surface antigen A (PsaA) (van der 
Poll and Opal, 2009). These factors participate in bacterial adherence, invasion, 
iron and other heavy metal transport, and oxidative stress protection (van der 
Poll and Opal, 2009). Other important factors that contribute to pneumococcal 
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virulence include host defense evasion, bacteriocin production, quorum sensing, 
and biofilm production (van der Poll and Opal, 2009). 
Due to the variability of the PC in combination with other virulence factors, 
all pneumococcal serotypes are not equally represented in the community and 
prevalence may vary slightly geographically and by age (Kalin, 1998). Most 
pneumococcal serotypes however are known to cause disease in humans 
(Yildirim et al., 2015). Interestingly, the serotype distribution of common 
colonizers of the nasopharynx is similar worldwide but certain serotypes tend to 
cause higher rates of invasive disease (Bogaert et al., 2004). Pneumococcal 
serotypes not only compete with one another, but are also affected by the use of 
the pneumococcal conjugate vaccine which, has altered serotype prevalence in 
the community (Kadioglu et al., 2008). Prior to widespread use of the 
pneumococcal conjugate vaccine in the United States the most common invasive 
serotypes in children under 5 years of age were 4, 6B, 9V, 14, 18C, 19F, and 
23F (Geno et al., 2015; Yildirim et al., 2015) while in older adults serotype 3 was 
a common cause of invasive disease (Geno et al., 2015). Following the 
introduction of the pneumococcal conjugate vaccine (targeting 7 serotypes) 
serotype 19A emerged as a dominant isolate in children and also increased in 
the elderly while serotype 3 remained prevalent in the elderly population (Pilishvili 
et al., 2010). Additionally, serotype 11A often colonizes children but is an 
uncommon cause of invasive disease while the same serotype often causes 
invasive disease in adults (Geno et al., 2015). The differential prevalence of 
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pneumococcal serotypes both during nasopharyngeal colonization and invasive 
disease is a complex issue that involves both pathogen and host factors and is 
further complicated as vaccine strategies evolve.  
As briefly mentioned above, pneumococcus is a common colonizer of the 
human nasopharynx, which is often referred to as carriage. Most of the time 
pneumococcal carriage is asymptomatic and the bacteria is able to exist as a 
commensal organism without causing overt disease (Jambo et al., 2010). Studies 
have shown that up to 60% of small children may carry pneumococci in their 
noses; this carriage rate peaks around 2-3 years of age and declines to <10% in 
adults (Henriques-Normark and Tuomanen, 2013). Pneumococcal carriage rates 
among children in developing countries are typically 2-3 times higher than in 
children in industrialized countries due to overcrowding, close contact with 
siblings, and frequent lung infections (Obaro and Adegbola, 2002). In a study of 
U.S. children Gray et al. found that during the first 2 years of life 95% of children 
were colonized at one point and 73% of those children were colonized with more 
than one serotype although typically on different occasions (Gray et al., 1980). 
The average carriage time was 2.5 to 4.5 months depending on the serotype, 
and with serial pneumococcal carriage the duration decreased (Gray et al., 
1980). It has also been noted that prolonged carriage of a pneumococcal 
serotype occurs but the development of diseases caused by that serotype is rare. 
Typically the disease-causing pneumococcal serotype is newly acquired. The 
development of host-acquired immune protection that contributes to these 
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observed phenomena will be addressed in a later section. Not only is 
pneumococcal carriage a required prerequisite for disease but it is also the 
method of horizontal transmission (person-to-person) through direct contact with 
a colonized individual (Kadioglu et al., 2008).  
 Pneumococcal colonization of the human upper airway is initiated through 
key bacterial factors that prevent rapid clearance and facilitate adherence to the 
nasal epithelium. The majority of pneumococcal serotypes have anionic or 
negatively charged capsules, which are thought to help prevent clearance by the 
mucus lining the surface of the nasal cavity via repulsion of the sialic acid-rich 
polysaccharides in mucus (Geno et al., 2015; Kadioglu et al., 2008). The ability of 
pneumococci to alter the amount of capsule that is produced is known as phase 
variation and these differences in colony morphology play a large role in 
colonization and invasive disease (Hammerschmidt et al., 2005). Two distinct 
states, transparent and opaque, can be observed (Bogaert et al., 2004; 
Henriques-Normark and Tuomanen, 2013). The transparent colony morphology 
predominates in the nasopharynx and is associated with decreased production of 
PC and increased production of cell wall-associated elements like choline binding 
proteins (CbpA) that promote attachment to host cells. Opaque colony 
morphology on the other hand predominates in invasive sites like the blood and 
is associated with increased PC production and decreased CbpA production 
(Henriques-Normark and Tuomanen, 2013). Once the pneumococcus reaches 
the apical surface of the resting (non-inflamed) host epithelial cell, the bacterial 
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neuraminidase breaks down mucus in order to expose the cell surface 
carbohydrate N-acetyl-glycosamine (Bogaert et al., 2004). This host cell surface 
receptor can then interact with the pneumococcal surface adhesin A (PsaA). In 
addition, the pneumococcal adhesin phosphorylcholine (ChoP) binds to the 
receptor for platelet-activating factor (rPAF) and activates a host cell signaling 
cascade that promotes internalization of pneumococci and transcellular migration 
through the respiratory epithelium and vascular endothelium (Bogaert et al., 
2004; Kadioglu et al., 2008). Another pneumococcal cell surface and choline-
binding protein, CbpA, binds to the polymeric Ig receptor on host cells and 
enhances migration through the mucosal barrier (Bogaert et al., 2004). 
Complicating factors such as prior influenza infection can also enhance 
pneumococcal adherence to the host epithelium through viral neuraminidase that 
can increase possible pneumococcal binding sites. While all of the factors that 
contribute to the conversion of nasopharyngeal colonization to symptomatic 
disease remain to be elucidated, once the pneumococci gain access to the lower 
lung and alveoli, most likely through aspiration, subsequent pneumonia can 
develop (Obaro and Adegbola, 2002).  
 
Diagnosis and Treatment of Pneumonia 
 Pneumonia is characterized by fever, cough, sputum production, 
shortness of breath, physical findings of consolidation, and leukocytosis, in 
addition to chest radiology that displays new lung infiltrates (Mandell et al., 2007). 
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The diagnosis of CAP in elderly patients can be difficult due to the common lack 
of cough, sputum production, elevated white cell count, and fever (Musher and 
Thorner, 2014). In addition, other syndromes can present with pneumonia-like 
symptoms. Following a CAP diagnosis, treatment decisions are based on the 
stratification of patients into cases requiring hospitalization and those that do not 
(Musher and Thorner, 2014). For inpatients with a CAP diagnosis it is 
recommended that an effort be made to determine the etiological agent so that 
treatment can be tailored to the specific pathogen. Methods such as gram 
staining and culture of sputum and blood, urinalysis of pneumococcal antigens, 
and polymerase chain reaction (PCR) analysis for other bacterial and viral agents 
are used to determine pathogen specificity (Musher and Thorner, 2014). Gram 
staining and culture of high quality sputum samples yield positive results in 80% 
of pneumococcal pneumonia patients, but this success diminishes with 
increasing time after antibiotic administration (Musher and Thorner, 2014). 
Determining the etiology of outpatient CAP is optional and generally not pursued 
due to the cost of diagnostic testing. Due to the time that it takes to determine the 
cause of CAP (if one is determined) patients are administered empirical 
antibiotics (Musher and Thorner, 2014). The IDSA/ATS (Infectious Diseases 
Society of America and the American Thoracic Society) guidelines for the 
treatment of inpatients with CAP recommend either beta-lactam plus macrolide 
or quinolone alone (Mandell et al., 2007). For outpatients without coexisting 
conditions administration of a macrolide or doxycycline is recommended by the 
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IDAS/ATS (Mandell et al., 2007). The choice of specific antibiotic can be 
substituted if a high level of resistance exists within the particular community. 
Duration of antibiotic therapy has varied over time but a course of 5 days is 
currently recommended to balance antibiotic stewardship and effective use to 
treat the infection (Musher and Thorner, 2014).  
Prevention: The Pneumococcal Vaccine 
 During the first half of the 20th century vaccines made with whole killed 
pneumococcus or purified capsular polysaccharide were developed and the 
results were promising. Interest waned in prevention of pneumococcal disease 
however shortly after the initiation of widespread use of penicillin to treat 
pneumococcal infection (Bridy-Pappas et al., 2005). The rise in the incidence of 
antibiotic resistant pneumococci renewed interest in preventing pneumococcal 
disease. The pneumococcal vaccines are targeted to the populations at the 
highest risk for disease: the very young, the old, and those that are 
immunocompromised. Pneumococcal vaccines are broken down into two major 
categories, pneumococcal polysaccharide vaccines (PPSV) and pneumococcal 
conjugate vaccines (PCV). Both formulations provide serotype-specific protection 
against the pneumococcal serotypes contained within the vaccine. PPSV are 
composed of purified pneumococcal capsular polysaccharide (CDC, 2015). The 
only PPSV available today is the 23-valent polysaccharide vaccine (PPSV23, 
Pneumovax) that was licensed in 1983. PPSV23 contains 23 pneumococcal 
polysaccharide antigens from serotypes that are responsible for 60-76% of 
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invasive disease (CDC, 2015). In 80% of healthy adults PPSV23 induces an 
antibody response 2-3 weeks after immunization, and the elevated antibody 
levels last for at least 5 years (Yildirim et al., 2015). There are however some 
limitations to the PPSV23 vaccine. The polysaccharides from the capsules of the 
23 select serotypes are T cell-independent immunogens meaning that they can 
stimulate B cells and induce antibody production in the absence of T cell help 
signals (Yildirim et al., 2015). Due to this inherent immunologic quality of 
capsular polysaccharides PPSV23 fails to generate immunologic memory and 
does not prime the immune system for a booster response following subsequent 
exposures (Geno et al., 2015; Yildirim et al., 2015). In addition this vaccine does 
not reduce nasopharyngeal colonization, its efficacy against noninvasive mucosal 
infections (pneumonia and otitis media) is limited, and it showed poor efficacy 
against invasive disease in chronically ill patients and in patients over the age of 
75 (Geno et al., 2015; Yildirim et al., 2015). Importantly, PPSV23 fails to 
generate antibody responses in young children under the age of 2 years, which is 
an especially susceptible population with a high incidence of pneumococcal 
disease (CDC, 2015; Geno et al., 2015).  
 In an effort to boost the immunogenicity of pneumococcal vaccines in 
children less than 2 years of age, the first pneumococcal conjugate vaccine 
PCV7 (Prevnar) was licensed in 2000 (CDC, 2015). This formulation consists of 
purified capsular polysaccharide from seven pneumococcal serotypes (4, 9V, 14, 
19F, 23F, 18C, and 6B) conjugated to CRM197, a nontoxic variant of diphtheria 
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toxin that induces T cell-dependent adaptive immune responses. The serotypes 
covered in PCV7 are the most common pneumococcal serotypes found in 
children under 5 years of age in the United States and overall account for 80% of 
all pneumococcal infections in children in developed countries (Pilishvili et al., 
2010; van der Poll and Opal, 2009). PCV7 proved to be highly immunogenic in 
young children and has subsequently reduced the incidence of invasive disease 
in U.S. children under the age of 5 by 75% with a 99% reduction in invasive 
disease caused by vaccine serotypes (Whitney et al., 2003; Yildirim et al., 2015). 
Nasopharyngeal colonization rates of vaccine serotypes have also been reduced 
due to PCV7. Those that are unvaccinated have benefited from herd protection 
and have seen a significant decline in invasive pneumococcal disease rates 
(Yildirim et al., 2015). Unlike PPSV23, PCV7 has shown efficacy against 
pneumococcal pneumonia by decreasing the incidence of X-ray-defined 
pneumonia in children (Lucero et al., 2009). While the effects of PCV7 have been 
substantial, multiple studies have reported serotype replacement with non-
vaccine serotypes causing increased invasive pneumococcal disease (Hicks et 
al., 2007). Serotype 19A, a non PCV7 serotype, was of special concern, causing 
43% of invasive disease cases prior to its inclusion in the next generation 
pneumococcal vaccine PCV13 (Prevnar-13) in 2010. PCV13, like PCV7, has also 
resulted in dramatic reductions in invasive disease through direct and herd 
immunity and in non-bacteremic pneumonia (Yildirim et al., 2015). There are 
limitations to the PCVs however. Firstly, they are expensive to produce and offer 
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coverage against only a small number of pneumococcal serotypes. Secondly, 
they have been shown to induce a serotype shift in non-vaccine serotypes 
causing disease (Jambo et al., 2010).  
 Currently the Advisory Committee on Immunization Practices (ACIP) in the 
U.S. recommends that children aged 2 to 59 months and children aged 60 to 79 
months with underlying conditions receive PCV13 as a routine vaccination even if 
they previously received PCV7 (Nuorti and Whitney, 2010). People 6 years of 
age and up who are immunocompromised should, even if they had any other 
pneumococcal vaccination, receive PCV13 followed by PPSV23 (CDC, 2015). 
For those 65 years and older, it is recommended that they receive PCV13 and 
PPSV23 in a series, with 6 to 12 months separating the doses (Tomczyk et al., 
2014).  
 An alternative universal vaccine strategy targeting conserved 
pneumococcal proteins (whole cell antigen-based vaccine) is being tested in 
animal models (Malley et al., 2001). This approach to vaccination would provide 
coverage against all pneumococci and would allow for the use of a single vaccine 
around the world without special considerations for serotype prevalence in 
different geographic regions (Jambo et al., 2010). In addition, a mucosal route of 
immunization is also being tested. One advantage of this route of immunization is 
that it mimics the natural route of pneumococcal infection. Intramuscular injection 
of the vaccine may not induce optimal trafficking of lymphocytes to the mucosal 
surfaces where they are most needed (Jambo et al., 2010). In fact, mucosal 
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immunization has been shown to induce protection against colonization of 
pneumococcus in a mouse model system (Malley et al., 2005; Pimenta et al., 
2006). Additionally there are data to suggest that mucosal immunization may 
also elicit better systemic and mucosal protection compared to traditional routes 
of delivery (Hanniffy et al., 2007).  
Innate Immune Responses and Pathology 
 Within days (1-3) of initial pneumococcal colonization of the upper airways 
of mice there is an influx of neutrophils that is likely due to the production of 
chemokines by epithelial cells in response to the pneumococcal virulence factor 
pneumolysin (Kadioglu et al., 2008). However, this influx fails to clear the 
colonizing pneumococci (Kadioglu et al., 2008). It is hypothesized that 
pneumococci may initiate inflammation via pneumolysin in order to stimulate 
secretions that may aid in the transmission of bacteria to other hosts despite the 
risk of clearance by host defenses (Kadioglu et al., 2008). Recent evidence 
suggests that adaptive immune host factors like cell-mediated and humoral 
immunity play an essential role in the defense against colonization and invasive 
disease. These topics will be discussed further in later sections.  
 When pneumococci reach the lower airways, firm adherence and 
subsequent replication along with host immune responses contribute to the 
development of a pneumonic disease state (Henriques-Normark and Tuomanen, 
2013). The recognition of pneumococcus as foreign by the host is the first step in 
mounting an immune response that is necessary to clear the infection. One of the 
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most important recognition systems that initiate immune responses are the 
pattern recognition receptors (PRRs). PRRs recognize evolutionarily conserved 
motifs expressed by pathogens, or pathogen associated molecular patterns 
(PAMPs). Toll-like receptors (TLRs), a type of PRR, are expressed in a wide 
variety of cells but are particularly enriched in immune cells (Takeda and Akira, 
2005). There are a number of TLRs in both humans and mice (models for human 
disease) that recognize a variety of conserved moieties on pathogens (Calbo and 
Garau, 2010; Takeda and Akira, 2005). TLRs are located on the outer plasma 
membrane and inside the cell on lysosomes and endosomes (van der Poll and 
Opal, 2009). During pneumococcal pneumonia TLR-2 recognizes the cell wall 
components peptidoglycan and lipoteichoic acid. In addition, TLR-4 binds to the 
pneumococcal cytotoxic factor pneumolysin and bacterial DNA is recognized by 
TLR-9 which has been shown to be essential for phagocytosis and killing of 
pneumococci by lung macrophages (Albiger et al., 2007). While airway epithelial 
cells do express TLRs and participate in the innate immune response, it is the 
sentinel cell, the alveolar macrophage, which uses these receptors along with 
others to initiate innate immune responses to pneumococci in the deep airways 
(Mizgerd, 2008; Yamamoto et al., 2014; Yamamoto et al., 2012). Alveolar 
macrophages are specialized cells that reside in the lungs and patrol the luminal 
surfaces of the alveoli (Mizgerd, 2008). They are uniquely positioned within the 
lungs and serve as the first line of defense against invading pathogens. 
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 In addition to TLRs macrophages also possess multiple classes of 
scavenger receptors that recognize endogenous modified self-molecules as well 
as conserved microbial structures (Canton et al., 2013). During pneumococcal 
pneumonia the class A scavenger receptor macrophage receptor with 
collagenous structure (MARCO) enhances binding and internalization of S. 
pneumoniae (van der Poll and Opal, 2009). Once the pneumococci are 
internalized they can be recognized by various cytoplasmic PRRs, an example of 
which is nucleotide-binding oligomerization domain protein (NOD). NOD2 binds 
to a portion of the pneumococcal peptidoglycan muramyl dipeptide (van der Poll 
and Opal, 2009). In the cytosol a mutli-protein complex called the inflammasome 
is also activated following infection with pneumococcus. This protein complex 
activates the enzyme caspase-1 that in turn activates important pro inflammatory 
signaling cytokines IL-1β, IL-18, and IL-33 (van der Poll and Opal, 2009).  
 Following recognition of pneumococcus through PRRs the internal 
signaling cascades that are initiated converge on signaling hubs that are 
essential for the immune response, an example of which is nuclear factor κB 
(NF-κB) (Mizgerd, 2008). NF-κB is a transcription factor that activates the 
production of pro inflammatory mediators like cytokines, chemokines, adhesion 
molecules, and colony-stimulating factors (Mizgerd, 2008). In a mouse model of 
pneumococcal pneumonia NF-κB (RelA) was necessary for the macrophage-
derived production of TNFα, CXCL1, CXCL2, and IL-1 during the early stages of 
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infection. Reduced production of these cytokines resulted in reduced neutrophil 
recruitment and increased lung bacterial burden (Pittet et al., 2011).  
 TNFα and IL-1 are two important macrophage-derived cytokines that drive 
early innate immune responses and stimulate the production of chemokines that 
recruit neutrophils to the infected airspaces from the bloodstream. In addition to 
neutrophil chemotaxis, TNFα and IL-1 also induce the production of granulocyte 
colony stimulating factor (G-CSF) and granulocyte-macrophage colony 
stimulating factor (GM-CSF), which stimulates the bone marrow to increase 
production of neutrophils, decreases maturation time, and stimulates the release 
of both mature and immature cells into circulation (Lawrence et al., 1996). 
Neutrophil infiltration into the infected airspaces is essential for bacterial 
clearance as they become the major phagocytosing cells that kill pneumococci 
(Calbo and Garau, 2010). Once neutrophils have internalized pneumococci via 
opsonophagocytosis the bacteria are housed in vesicles called phagosomes that 
fuse with pre-formed granules containing various antimicrobial compounds like 
reactive oxygen species (ROS) and lytic enzymes (Nordenfelt and Tapper, 
2011). While neutrophils are exceptional at killing foreign microbes, their 
mediators can have deleterious effects on the surrounding host tissues and their 
functions therefore must be tightly regulated (Mizgerd, 2008; Nordenfelt and 
Tapper, 2011). The accumulation of extravascular plasma fluids is necessary for 
the extravasation of serum components that aid immune defenses but also 
results in pulmonary edema, a hallmark of acute lung injury (Mizgerd, 2008). A 
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delicate balance of innate immune inflammation and control mechanisms must 
be maintained in order to rid the host of infection without causing excessive lung 
injury.  
 
Adaptive Immune Responses to Pneumococcal Pneumonia 
Anti-Pneumococcal Antibodies 
 The importance of anti-polysaccharide capsular antibodies has been 
demonstrated historically through the success of serum therapy and 
polysaccharide vaccines in the treatment and prevention of invasive 
pneumococcal disease. During early innate immune responses to pneumococcal 
nasopharyngeal colonization B cells are activated through PRRs and/or the 
binding of complement components to the receptors CD21 and CD35 (Zhang et 
al., 2015). Antigen-specific activation of naïve B cells occurs when the B cell 
receptor (BCR) comes into contact with its cognate antigen, in this case capsular 
polysaccharide (T-independent antigen stimulation), which can induce 
differentiation into an immunoglobulin M (IgM)+-secreting B cell (Zhang et al., 
2015). As the immune response progresses both pneumococcus-specific 
mucosal secretory IgA and systemic IgG are produced by antibody-secreting 
plasma cells, and activated B cells can further differentiate into memory cells 
(Richards et al., 2010; Zhang et al., 2015). These antibodies opsonize the 
pneumococci and not only enhance phagocytosis and clearance but also disrupt 
the adherence of pneumococci to the respiratory epithelium (Jambo et al., 2010). 
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Decreased duration of pneumococcal carriage in adults as compared to children 
has been correlated with an increase in anti-capsular secretory IgA and high 
serum anti-capsular IgG (Goldblatt et al., 2005; Richards et al., 2010; Simell et 
al., 2002). While it is clear that anti-capsular antibodies are very effective in the 
prevention of invasive pneumococcal disease, it is important to determine if this 
mechanism represents the primary mode of protection during the natural 
development of resistance (Malley, 2010).  
 Antibodies that target the polysaccharide capsule of pneumococcus have 
been the main focus of the research and medical fields, but nasopharyngeal 
colonization also elicits antibodies capable of binding to cell wall components 
such as PspA, PsaA, and pneumolysin (Malley, 2010). These protein elements 
common to the species were discussed briefly above as pneumococcal virulence 
factors. Antibodies against these common pneumococcal elements have been 
shown to be protective against invasive disease through active and passive 
immunization (Briles et al., 1998).  
 Many studies have demonstrated that anti-pneumococcal antibodies play 
a crucial role in protection against invasive disease, but recent studies have tried 
to determine their importance in preventing nasopharyngeal colonization as it is 
the precursor to pneumococcal disease. Interestingly, studies done in 
experimental mouse models of pneumococcal colonization have shown that 
elimination of carriage is independent of both B cell function and pneumococcus-
specific antibody production (McCool and Weiser, 2004). If anti-polysaccharide 
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capsule antibodies were the primary mechanism of immune defense against 
pneumococcal carriage one would expect that acquisition of natural protection 
would vary widely between the serotypes depending on prevalence and 
exposure patterns, and antibody concentrations. In fact, using the incidence data 
in the U.S. one group found that a substantial decline in the incidence of 
serotype-specific pneumococcal disease around 2-3 years of age was not 
associated with an appreciable increase in antibody concentrations (Lipsitch et 
al., 2005). These data suggest that other mechanisms of immune protection 
against pneumococcal colonization and therefore disease are likely involved.  
The Role of CD4+ T cells in pneumococcal Colonization and Disease 
 The critical role of CD4+ T cells in pneumococcal infection and disease 
can been seen in HIV-infected patients who frequently develop severe infections 
and are more likely to be constantly colonized by pneumococci (Redd et al., 
1990; Rodriguez-Barradas et al., 1997). In addition, mice that lack major 
histocompatibility complex class II (MHC-II), an essential molecule for CD4+ T 
cell antigen-specific activation, demonstrate extended pneumococcal carriage 
(Malley et al., 2005). In this study, mice that were colonized with different 
serotypes of live pneumococcus were protected from recolonization by the 
homologous and also heterologous serotypes independent of anti-capsular 
antibodies (Malley et al., 2005). Mice depleted of CD8+ T cells were fully 
protected, but protection was lost in CD4+ T cell deficient mice (Malley et al., 
2005). Further studies in a mouse model of pneumococcal colonization 
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confirmed that the T cell-mediated immunity that provided protection against 
colonization was antigen-specific (Trzcinski et al., 2008). Several groups have 
gone on to show that the effector mechanism of pneumococcus-specific CD4+ T 
cells generated following mucosal immunization is the proinflammatory cytokine 
interleukin 17A (IL-17A) (Malley et al., 2006; Zhang et al., 2009). Neutralization of 
IL-17A in mice immunized with the species-common cell wall polysaccharide 
(plus a mucosal adjuvant to boost cell-mediated immunity) reduced protection 
against subsequent experimental colonization (Malley et al., 2006).  
 IL-17A is the primary effector cytokine of a subset of CD4+ T-helper cells 
abbreviated as Th17 cells although it can be produced by other cell types such 
as gamma-delta T cells depending on the setting (Curtis and Way, 2009). Th17 
cells play an important role in the clearance of extracellular pathogens, but have 
also been implicated in tissue damage and pathogenesis (Korn et al., 2009). 
When produced at mucosal sites by activated Th17 cells, IL-17A can induce 
signaling in epithelial and stromal cells that results in the production of colony 
growth factors like G-CSF and chemokines like CXCL1 and CXCL2. These 
factors stimulate granulopoiesis and neutrophil recruitment, respectively, to the 
site of infection (Aujla et al., 2007). 
 If pneumococci colonizing the nasopharynx are aspirated and reach the 
lower airways or alveoli they will encounter the lung immune defenses, of which 
the innate response was discussed above. Sentinel pulmonary dendritic cells 
extend into the airway lumen in order to ingest and sample the contents 
  
26 
(Mizgerd, 2008). Once these cells are activated by the ingestion of invading 
pneumococci in the airway and by the surrounding inflammatory environment 
they mature into professional antigen-presenting cells (APCs) and migrate to the 
regional draining lymph node where they can activate antigen-specific naïve T 
cells (Jambo et al., 2010). The T helper subset fate decision is largely 
determined by the cytokine signals provided by the APC (van Beelen et al., 
2007). Th17 cell development is stimulated by the cytokines transforming growth 
factor beta (TGF-β) and interleukin 6 (IL-6) (van Beelen et al., 2007). Then, 
during the later stages of infection effector memory T helper cells are recruited in 
large numbers to the lung, a time that coincides with pneumococcal clearance 
(Zhang et al., 2009). Following the primary pneumococcal infection antigen-
specific memory Th17 cells are primed for a recall response. A secondary 
pneumococcal challenge then results in rapid IL-17 production and neutrophil 
recruitment for efficient bacterial clearance (Zhang et al., 2009).  
 In a mouse model of pneumococcal colonization and secondary challenge 
both Th17 (including IL-17A) cells and anti-pneumococcal antibodies were 
required for protection against a homologous pneumonia (non-bacteremic) 
challenge (Wilson et al., 2015). Prior nasopharyngeal pneumococcal colonization 
established adaptive immunity that resulted in a reduced bacterial burden in the 
lungs following a pneumococcal infection (Wilson et al., 2015). Th17 cells were 
not required however for clearance of systemic pneumococci following an 
invasive challenge of previously colonized mice (Cohen et al., 2011). Antibody-
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mediated phagocytosis was responsible for the rapid clearance of bacteria from 
the blood (Cohen et al., 2011). IL-17 has also been shown to be important for 
defense against another important pulmonary pathogen, Klebsiella pneumoniae, 
a bacterium that also differentially expresses capsular polysaccharide (Chen et 
al., 2011). Following mucosal immunization with killed K. pneumonia mice 
displayed a robust mucosal Th17 response that was required for protection 
against a heterologous (different strain than the immunization) pneumonia 
challenge (Chen et al., 2011). The antibodies generated by mucosal 
immunization were largely capsular polysaccharide specific and therefore the 
protection they afforded was restricted to the vaccine strain (Chen et al., 2011). 
Using a co-culture system of human monocytes and CD4+ T cells another group 
sought to understand the host and bacterial factors that mediate memory T 
helper cell responses to both live and killed pneumococci in order to aid future 
vaccine development (Olliver et al., 2011). They found that monocytes stimulated 
memory T helper cells to produce both IFN-γ and IL-17A, which are Th1 and 
Th17 effector cytokines, respectively (Olliver et al., 2011). Interestingly, the 
balance between IFN-γ and IL-17A production depended on the viability of the 
bacteria used for stimulation. IL-17A was induced both by live pneumococcus 
and heat-killed bacterial stimulation, whereas IFN-γ was induced only in 
response to live bacteria (Olliver et al., 2011). The production of IL-17A and IFN-
γ was dependent of differential immune signaling pathways, TLR2 and 
monocyte–derived IL-12p40, respectively (Olliver et al., 2011). These reports 
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highlight the importance of a vaccination strategy that induces not only anti-
pneumococcal antibody production but also memory T helper cells.  
 
Tissue-Resident Memory Cells 
 Before the discovery of tissue-resident memory T cells (TRM) it was 
thought that T cells were recruited to sites of inflammation from the blood or 
secondary lymphoid structures and that uninflamed peripheral tissues contained 
few T cells (Clark, 2015). Antigen-specific CD4+ or CD8+ T cells are activated, 
undergo clonal expansion, mature info effectors cells and migrate to the site of 
inflammation. After resolution of the infection the majority of effector cells 
undergo apoptosis but a small number have the capacity to become long-lived 
memory cells, representing a fundamental arm of life-long pathogen protection 
(Farber et al., 2014). These diverse populations of memory T cells exist in 
multiple locations ready to respond rapidly upon antigen re-exposure (Farber et 
al., 2014). Until recently, memory T cells were broken down into two subsets, 
central memory T cells (TCM), which express CCR7 and CD62L, and effector 
memory T cells (TEM) cells, which do not express these cell surface markers 
(Mueller et al., 2013). TCM cells, both CD4
+ and CD8+, are predominant in 
secondary lymphoid organs and are highly proliferative (Mueller et al., 2013). TEM 
cells on the other hand are less proliferative and produce immunomodulatory 
effector cytokines such as IFN-γ and IL-17 in addition to displaying 
heterogeneous migratory capacity (Mueller et al., 2013). Recently, a non-
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circulating memory T cell subset that remains in the peripheral tissue after the 
resolution of infection and inflammation has been named TRM (Mueller et al., 
2013).  
 Some of the first observations of TRM cells were made in 2001 when it was 
reported that following the resolution of an influenza infection in mice CD8+ cells 
remained in the lung long-term (Hogan et al., 2001b). In another study antigen-
specific CD8+ cells migrated to and persisted in nonlymphoid tissues such as the 
lung, liver, and small intestine after both viral and bacterial infections (Masopust 
et al., 2001). Upon ex-vivo stimulation these cells responded with more effector 
function (lytic activity) potential than splenic CD8+ memory cells (Masopust et al., 
2001). In humans, it was estimated that normal healthy skin contains 20 billion T 
cells twice as many as in circulation (Clark et al., 2006). These skin T cells not 
only expressed the memory marker CD45RO and the skin-homing surface 
molecules cutaneous lymphocyte antigen (CLA) and CCR4, but also possessed 
a diverse T cell repertoire (Clark et al., 2006). Human lungs, gastrointestinal 
tract, reproductive tract, and bone marrow all contain a large number of T cells 
with a wide range of antigen specificities (Clark, 2015). 
 Much of what is known about tissue-resident memory is in the setting of 
viral infections in mouse models, and as a result more information has been 
gathered about CD8+TRM due to less efficient generation of CD4
+TRM in this 
context (Park and Kupper, 2015). There is however increasing evidence of 
nonlymphoid memory CD4+ T cell populations (Reinhardt et al., 2001). The 
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anatomic location of draining lymph nodes where naïve T cell activation takes 
place seems to play a large role in the tissue tropism of the newly activated T 
cells through the differential induction of tissue-specific homing receptors (Park 
and Kupper, 2015). For example, naïve T cells activated in gut-draining lymph 
express integrin α4β7, the receptor for the mucosal addressin cell-adhesion 
molecule (MAdCAM) that is expressed by epithelial cells in the intestinal lamina 
propria in addition to CCR9, a chemokine receptor specific for intestinal 
chemokine CCL25 (Briskin et al., 1997; Zabel et al., 1999). In a model of 
localized skin infection by vaccinia virus CD8+ cells were rapidly recruited to the 
skin independent of CD4+ T cells and remain in the skin as long-lived CD8+ TRM 
cells (Jiang et al., 2012). These CD8+ TRM cells are potent effector cells upon re-
infection of the skin and not only seed the site of infection but distribute 
throughout the entire skin surface (Jiang et al., 2012). Both TCM and TRM are 
generated following a skin-localized infection, but until recently there was little 
information about the clonal origin of these cells, whether they are derived from a 
common clone or separate cells due to different differentiation signals. A recent 
study analyzed antigen-activated T cells from different anatomical sites following 
skin immunization with three different antigens (Gaide et al., 2015). By 
sequencing the variable regions of the T cell receptors (TCR) and comparing the 
sequences obtained from different sites (i.e., site of immunization vs. distant 
lymph node) they found identical TCR sequences in both the TRM and TCM-
defined cell populations (Gaide et al., 2015). It seems that at least in some 
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circumstances TCM and TRM can develop from a single activated naïve T cell and 
distribute throughout the body.  
Common Features of TRM cells 
 A common theme of tissue-resident memory is that the cells do not 
circulate in the blood or lymph nodes, but the mechanisms that govern the 
recruitment and retention of these cells in the tissue is an active area of research 
(Jiang et al., 2012; Mueller et al., 2013). CD69, a marker originally thought of as 
an activation marker, has been identified as an important marker of TRM cells in 
every tissue in which they have been studied (Hogan et al., 2001a; Mackay et al., 
2013; Sheridan et al., 2014). It was reported that CD69 influences the tissue 
retention of skin localized CD8+ TRM cells following HSV infection by interfering 
with the sphingosine-1-phosphate receptor 1 (S1Pr1) function, which controls 
movement of T cells to and from lymphoid structures (Mackay et al., 2015). 
Another molecule shown to be a marker of TRM is the integrin CD103, which is 
expressed more predominantly on CD8+ TRM rather than CD4
+ TRM cells (Park 
and Kupper, 2015). CD103 is a ligand of the adhesion molecule E-cadherin that 
is expressed on barrier tissue epithelial cells (Park and Kupper, 2015). Studies of 
HSV skin infection in mice have demonstrated that antigen-specific CD8+ T cells 
did not express CD103 prior to entry into the tissue (skin) and that this marker 
was then upregulated via transforming growth factor-β (TGF-β) (Mackay et al., 
2013). The role of CD103 is complicated however, because E-cadherin binding is 
not required for tissue residence as CD103+CD4+ and CD8+ TRM cells can be 
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found in the dermis in addition to CD103+ dendritic cells (Park and Kupper, 
2015). CD103 may not be functionally required for tissue residence but rather a 
marker of a subtype of TRM cells. 
CD4+ TRM cells in the Mucosa 
 While the majority of TRM research has focused on CD8
+ T cells following 
viral infections, according to a recent human study, CD4+ T cells are the most 
abundant lymphocyte in the body (Ganusov and De Boer, 2007; Sathaliyawala et 
al., 2013). In the mucosal and barrier tissues memory CD4+ T cells outnumber 
memory CD8+ T cells (Ganusov and De Boer, 2007; Sathaliyawala et al., 2013). 
Like CD8+ TRM cells CD4
+ TRM cells are non-circulating and retained in specific 
tissues after the resolution of infection and inflammation (Turner and Farber, 
2014). CD4+ TRM cells have been found in many normal human tissues, including 
the lungs (Purwar et al., 2011; Sathaliyawala et al., 2013). CD4+ TRM cells are 
also identified by the expression of CD69 in addition to the integrin CD11a and 
have been found in the skin, lungs, and intestines of mice (Purwar et al., 2011; 
Teijaro et al., 2011; Turner et al., 2014). Most CD4+ TRM cells do not express 
CD103 except for a small proportion in the skin (Gebhardt et al., 2011; Turner 
and Farber, 2014). So far it is not known whether CD4+ TRM cells express other 
tissue-specific integrin or adhesion markers (Turner and Farber, 2014). When 
stimulated, CD4+ TRM cells can produce effector cytokines such as IFN-γ and IL-
17, but more studies are needed to better understand the functional differences 
between circulating and tissue-resident memory CD4+ cells.  
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 As a barrier tissue that is constantly exposed to foreign particles and 
potential pathogens, it is not surprising that the respiratory tract contains a large 
number of both CD4+ and CD8+ TRM cells with extensive repertoire heterogeneity. 
A distinct CD4+ TRM population was characterized after influenza infection in the 
lungs of mice using an in vivo labeling technique that identifies cells that are 
accessible to the circulation while those that are not are left unlabeled (Teijaro et 
al., 2011; Turner et al., 2014). Unlabeled CD4+ cells expressed high levels of 
CD69 and CD11a and were located in close proximity to airways (Turner et al., 
2014). When the CD4+ lung-resident cells were adoptively transferred into 
congenic hosts they specifically migrated to the lungs whereas spleen-resident 
memory cells migrated to multiple tissues (Teijaro et al., 2011). Mycobacterium 
tuberculosis (Mtb) infections in mice have also been shown to generate 
pathogen-specific CD4+ TRM cells that are retained in the lungs (Sakai et al., 
2014). The lungs of Mtb-exposed human subjects also contain CD4+ T cells with 
a memory phenotype that produced IFN-γ when stimulated with Mtb antigen 
(Walrath et al., 2005). The presence of pathogen-specific CD4+ TRM cells at the 
site of infection is thought to provide a rapid recall response in situ upon 
reinfection. Following a secondary viral infection in mice CD4+ lung TRM cells 
rapidly produced the effector cytokine IFN-γ and were found to provide better 
protection against reinfection than spleen-derived CD4+ memory cells (Teijaro et 
al., 2011; Turner et al., 2014); the same was true during a secondary infection 
with Mtb (Sakai et al., 2014). The protective mechanisms that lung CD4+ TRM 
  
34 
cells confer are an open field of investigation. Additionally, the ability of primed 
CD4+ TRM cells to induce inflammation and recruit additional cells means that 
they also could be involved in immunopathogenic responses that damage the 
surrounding tissues. Pathogenic TRM cells have been implicated in human 
diseases like psoriasis (Park and Kupper, 2015). These observations stress the 
importance of understanding the generation, maintenance, and effector functions 
of TRM and how these processes might induce immunopathology. 
 
Memory B cells and Plasma Cells 
 A cornerstone of long-term immunological memory and protection against 
reinfection is the development of both memory B and long-lived plasma cells. 
The classical pathway of differentiation of an antigen-bound B cell involves T cell-
dependent stimulation that leads to the production of high-affinity antibodies and 
memory B cell development (Chiu and Openshaw, 2015). Antigen-loaded mature 
DCs migrate to secondary and tertiary lymphoid structures where naïve B cells 
can recognize their cognate antigen. An example of a tertiary lymphoid structure 
is the inducible bronchus-associated lymphoid tissue (iBALT) that can form 
during certain viral respiratory infections (Chiu and Openshaw, 2015). Once 
activated by its specific antigen, a B cell migrates towards the edge of the B cell 
follicle in the secondary lymphoid tissue in order to form a stable interaction with 
an antigen-activated CD4+ T cell at the edge of the T cell follicle (Kurosaki et al., 
2015). This interaction involves presentation of the antigen by the B cell in the 
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context of MHC-II to the CD4+ T cell. During this stable interaction the CD4+ T 
cell provides differentiation and activation help in the form of costimulatory CD40-
CD40L interaction and production of the cytokines IL-4, IFN-γ, and TGF-β (Chiu 
and Openshaw, 2015). These helper signals stimulate isotype class switching 
from IgM to IgG or IgA in addition to enhancing proliferation (Chiu and 
Openshaw, 2015). Some of the proliferating B cells differentiate into 
extrafollicular short-lived plasma cells that meditate immediate protection and 
pathogen clearance in addition to memory cells that are germinal center-
independent (Kurosaki et al., 2015; Yoshida et al., 2010). Other proliferating B 
cells move into the follicle and form the germinal center where somatic 
hypermutation and affinity maturation occur with the help of specialized CD4+ 
follicular helper T cells (TFH) (Chiu and Openshaw, 2015). After multiple rounds of 
selection for high-affinity B cell receptors (BCRs) the surviving B cells can exit 
the germinal center as memory cells or long-lived plasma cells (Chiu and 
Openshaw, 2015; Kurosaki et al., 2015). Long-lived plasma cells migrate to 
special niches like the bone marrow where they survive and contribute circulating 
pathogen-specific antibodies (Yoshida et al., 2010). Memory cells are quiescent 
in lymphoid tissues as they await reactivation during a secondary infection. The 
potential longevity of memory B cells has been demonstrated in humans who 
possess smallpox-specific memory B cells more than 50 years after vaccination 
(Crotty et al., 2003). Upon antigen re-exposure, memory cells rapidly differentiate 
into antibody-secreting plasma cells and also into the next generation of memory 
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cells in order to replenish the protective pool (Kurosaki et al., 2015). The 
distribution and maintenance of memory B cells in different infection contexts and 
anatomical regions remains an active area of research due to the importance of 
these cells for protection against reinfection and vaccine development.  
 Similar to the concept of lung TRM cells, it has also been demonstrated that 
memory B cell populations can remain in the lungs following the resolution of a 
lung infection. Many studies have shown that in the context of a viral lung 
infection, especially influenza, B cells accumulate in the lungs and are poised to 
respond via neutralizing antibody production upon reinfection (Joo et al., 2008; 
Onodera et al., 2012). Evidence of germinal center formation and lymphoid cell 
aggregation has also been reported following viral lung infection (Adachi et al., 
2015; Vu Van et al., 2016). These studies also highlight an important role for 
another subset of T cell, the follicular T helper cell, in supporting lung-localized B 
cell populations (Boyden et al., 2012; Vu Van et al., 2016). While the role of anti-
pneumococcal antibodies was discussed above, to our knowledge it has not 
been demonstrated that the resolution of pneumococcal infections induces the 
retention of memory B cells in the lungs.  
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CHAPTER TWO: METHODS AND MATERIALS 
 
Mice 
 Female C57BL/6J mice used in heterotypic experiments were purchased 
from Jackson Laboratories (Bar Harbor, Maine) and maintained in specific 
pathogen-free conditions at Boston University Medical Center. Experiments were 
initiated when mice were 6-15 weeks of age. All animal protocols were approved 
by the Boston University Institutional Animal Care and Use Committee. 
Ighmtm1cgn mice (µMT B cell-deficient mice) 
 B cell-deficient mice generated via disruption of the immunoglobulin heavy 
chain mu (IgM) gene were originally developed by Dr. Klaus Rajewsky and Dr. 
Werner Muller at the University of Cologne, Germany (Kitamura et al., 1991). 
µMT mice on a C57BL/6 background were purchased from Jackson Laboratories 
and maintained at BUMC animal facilities by breeding homozygous animals. 
C57BL/6 mice purchased from Jackson Laboratories were used as wild type 
controls in µMT experiments.  
 
Bacteria 
 Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan was 
purchased from ATCC (43816, Manassas, VA).  
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Streptococcus pneumoniae  
 S. pneumoniae serotype 19F (Sp19F, EF3030) was kindly provided by Dr. 
Marc Lipsitch, Boston, MA. S. pneumoniae serotype 3 (Sp3) was purchased from 
ATCC (6303). S. pneumoniae serotype 23A (Sp23A) and serotype 35B (Sp35B) 
were isolated from nasopharyngeal swabs of children during well visits by 
Massachusetts healthcare providers and obtained from Dr. Stephen Pelton at 
BUMC.  
 For frozen stocks bacteria were grown overnight on blood agar plates 
(Trypticase Soy Agar) with sheep blood (BD Biosciences) at 37°C with 5% CO2 
and then restreaked on blood agar plates the following day for 5 hours. Bacteria 
were suspended in brain-heart infusion media (BHI, Remel) or Lysogeny broth 
(LB, Sigma) plus 16-20% glycerol and stored at -80°C. For experiments all 
bacteria were grown at 37°C with 5% CO2 for 14-16 hours on blood agar plates 
from frozen stock.  
Killed pneumococcus 
 In experiments where mice were exposed to heat-killed Sp19F, bacteria 
were suspended in sterile saline at a dose of 1-3 x 106 colony-forming units 
(CFU) per mouse (see intranasal infections) and incubated in a 55ºC water bath 
for 45 minutes. Killed bacteria suspensions were applied to blood agar plates to 
ensure no living Sp19F remained. Aliquots were stored at -80°C 
 Killed Sp3 for the ex vivo stimulation assays was prepared by growing Sp3 
on blood agar plates overnight and suspending approximately 5.3 x 109 CFU/mL 
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bacteria in Lactated Ringer’s solution (LR). The bacteria were washed twice with 
LR at 4°C and pelleted by spinning at 12,000xg for 5 minutes. Washed bacteria 
were resuspended in LR with 10% sucrose plus beta-propiolactone (BPL, Sigma) 
at a 1:4000 vol/vol ratio (Lu et al., 2010b). The mixture was then rotated for 24 
hours at 4°C followed by a heat-inactivation of BPL at 37°C for 2 hours. Killed 
bacteria suspensions were applied to blood agar plates to ensure no living Sp3 
remained. Aliquots were stored at -80°C. 
 
Mouse Infections 
Intranasal (i.n.) 
 Frozen bacterial stocks were grown overnight on blood agar plates for 14-
16 hours. The following morning cultures were restreaked on blood agar plates 
for 5 hours. Bacteria were suspended in sterile saline to an absorbance at 600 
nm of 0.3 and further diluted in order to obtain a dose of 1-3 x 106 CFU/mouse. 
Intranasal instillations were performed by anesthetizing mice with a ketamine (75 
mg/kg) and xylazine (5 mg/kg) mixture via intraperitoneal (i.p.) injection and 
applying a 10 µL bacteria suspension to each nares (20 µL total per mouse) until 
it was inhaled completely. 
Intratracheal (i.t.) 
 Frozen bacterial stocks were grown overnight on blood agar plates for 14-
16 hours. Bacteria were suspended in sterile saline to an absorbance at 600 nm 
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of 0.3 and further diluted in order to obtain a dose of 1 x 106 CFU per mouse 
(except for survival study and K. pneumoniae infection). Mice were anesthetized 
with ketamine (as above) and a small incision was made to expose the trachea. 
A 24-gauge catheter was inserted into the trachea and then into the left 
bronchus. A 50 µL bolus of bacteria was instilled into each mouse.  
Intraperitoneal (i.p) 
 A systemic pneumococcal challenge was achieved by injecting 100 µL of 
Sp3 suspended in sterile saline into the peritoneal cavity. Frozen bacterial stocks 
were grown overnight on blood agar plates for 14-16 hours and suspended in 
sterile saline at an absorbance of 0.3 at 600 nm and further diluted in order to 
obtain a dose of 3 x 102 CFU per mouse.  
 
Models of Heterotypic Immunity 
Intranasal Exposures 
 For heterotypic immunity, mice were serially infected i.n. with 1-3 (as 
specified) self-limiting doses of Streptococcus pneumoniae serotype 19F 
(EF3030, Sp19F), serotype 35B (Sp35B), or serotype 23A (Sp23A), with one 
week intervals between such serial infections. These mice are referred to as Het 
Imm (i.n.); control mice received i.n. instillations of sterile saline (Figure 1A). Mice 
were rested for 4 to 8 after the final infection or saline instillation and were then 
analyzed further or enrolled in pneumonia challenge experiments. 
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Intratracheal Exposures 
 In some experiments, as specified, mice were infected intratracheally (i.t.) 
in the left lobes with 2 doses of Sp19F one week apart. Hereafter, these are 
referred to as Het Imm (i.t.); control mice received i.t. sterile saline (Figure 1B). 
Infections were with 1-3 x 106 CFU per mouse for all serotypes. Mice were rested 
for 4 to 8 after the final infection or saline instillation and were then analyzed 
further or enrolled in pneumonia challenge experiments. 
Pneumonia  
 Streptococcus pneumoniae serotype 3 (Sp3, ATCC 6303) was instilled i.t. 
at a dose of 1 x 106 CFU unless otherwise stated for pneumonia challenges. 
Klebsiella pneumoniae (ATCC 43816) was instilled i.t. at a dose of 5 x 104 CFU 
per mouse. Bacterial burden was measured in the lungs and blood at the 
specified time points.  
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Figure 1: Models of naturally-acquired heterotypic immunity 
Mice were serially infected with 1-3 x 106 CFU of different pneumococcal 
serotypes either i.n. (A) or i.t. (B). Mice were allowed to recover for 4 to 8 weeks 
and then were challenged with i.t. Sp3 pneumonia or, non-pneumonic lungs were 
processed for other assays.  
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Measurements of bacterial burden 
 To assess bacterial burden mice were euthanized at specified time points 
by isoflurane overdose and whole lungs were removed and homogenized (Bullet 
blender, Next Advance) in water containing protease inhibitor (Roche). Lung 
suspensions were brought up to 5 mL, serially diluted and plated on blood agar 
plates overnight at 37°C so that colonies could be counted. Blood was collected 
in heparinized syringes from the inferior vena cava and serially diluted and plated 
on blood agar plates overnight at 37°C to assess bacteremia. Data are 
expressed as CFU per lung or CFU per mL respectively. Blood plasma was 
separated from erythrocytes by centrifugation at 1500xg for 15 minutes at 4°C. 
Plasma was collected and stored at -80°C.  
 
Lung Histology 
 After euthanasia and heart ligation lungs were isolated and inflated with 
4% paraformaldehyde (PFA) at 23 cm H2O pressure for fixation. Lungs were 
submerged in 4% PFA overnight. The following day the PFA was removed and 
the left lobes were cut into three sections and placed in a cassette. The lungs 
were treated with the solutions in Table 1 for the specified times and 
temperatures. Left lobe sections were embedded in paraffin blocks and a 
microtome was used to cut 5 µm thick sections which were affixed to glass 
slides. Hemotoxylin and eosin (H&E) staining was performed on sections from 
the specified groups and time points.  
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Table 1: Paraffin embedding protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bronchoalveolar Lavage 
Mice were euthanized at indicated time points and lungs were removed 
and secured to a blunted 20-gauge needle via the trachea and inflated with 1 mL 
ice cold PBS. The liquid was then withdrawn and the process was repeated until 
the lungs had been lavaged with a total of 10 mL PBS. The first milliliter was 
collected in a separate syringe and stored at -80°C for future protein analysis 
after all cells had been removed. Cells from the lavage were collected by 
centrifugation and counted using a hemocytometer. 1 x 105 cells were affixed to 
Solutions Incubation Time Temperature (°C) 
PBS 45 min on ice 
0.85% NaCl 45 min on ice 
1:1 Ethanol: 0.85% NaCl 30 min RT 
2X 70% Ethanol 30 min each RT 
80% Ethanol 1 hr RT 
90% Ethanol 1 hr RT 
3X 100% Ethanol 30 min each RT 
3X xylene 45 min each RT 
1:1 xylene: paraffin 2 hrs 60 
2X paraffin 1 hr each 60 vacuum 
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a glass slide using a cytospin (Cytospin 4, Thermo Scientific). Neutrophil and 
macrophage differential cell counts were determined after the cytospins had 
been stained with Diff-quik solutions (Dade-Behring).  
 
Cytokine Protein Measurements 
 Cytokine protein levels were measured in two different sample types: 
whole lung homogenates and ex vivo CD4+ T cell stimulation supernatants. 
Whole lung homogenates were prepared by incubating homogenized and diluted 
whole lungs (same samples from bacterial burden assays) with 20X cytokine 
protein extraction buffer for 30 minutes on ice. The samples were centrifuged at 
4°C and 10,000xg for 20 minutes. Supernatants were aliquoted and stored at -
80°C. Cell culture supernatants were collected at the specified time point and 
centrifuged to remove cells. The cell-free supernatants were stored at -80°C for 
protein analysis. 
Single-Plex Enzyme-Linked Immunosorbent Assays (ELISAs) 
 IL-17A, IL-22, TNF-α, G-CSF, CXCL1, CXCL13, and IFN-γ protein 
concentrations were measured using single-plex DuoSet ELISA kits purchased 
from R&D Systems (Minneapolis, MN). All ELISA kits were performed according 
to the manufacturer’s instructions.  
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Multi-plex Bead Arrays (Luminex) 
 Cytokine concentrations in BALF and cell culture supernatants were 
assessed using a Bio-plex magnetic bead assay (Luminex, R&D) and analyzed 
using a Bio-Plex 200 workstation (Bio-Rad). The BALF cytokine panel included 
granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, CXCL1, 
CXCL2, CXCL5, CCL20, IL-23p19, IL-17A, and TNF-α (R&D Systems). Cytokine 
concentrations in ex vivo CD4+ T cell stimulation supernatants were measured 
using a Luminex panel for IL-17A, IFN-γ, IL-2, TNF-α, IL-4, and IL-10 (R&D 
Systems). All Luminex assays were performed according to the manufacturer’s 
instructions.  
 
Collagenase Lung Digestion 
 For experiments that required lung single-cell suspensions, Type 2 
collagenase (Worthington Biochemical, Lakewood, NJ) was used to digest the 
lungs. Lung lobes were isolated and stored in RPMI-1640 media (Life 
Technologies, Carlsbad, CA) on ice following euthanasia of mice at the specified 
time points. Lungs were removed from RPMI media and placed in 5 mL of 
digestion solution (Type 2 collagenase 1 mg/mL, DNase I 150 µg/mL, CaCl2 2.5 
mM in phosphate-buffered saline, PBS), minced with a razor blade, and 
transferred to a 50 mL conical tube. The digestion mixture was incubated at 37°C 
with shaking at 250 revolutions per minute (RPM) for 1 hour. Following the 
incubation the lung mixture was passed through a 70 µm cell strainer (Fisher, 
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Grand Island, NY) and the remaining pieces were pushed through the strainer. 
Cells were then pelleted via centrifugation and resuspended in 1 mL red blood 
cell lysis buffer (Sigma, St. Louis, MO) for 1 minute at room temperature. To stop 
the lysis 10 mL PBS was added to each sample and cells were pelleted again by 
centrifugation. Single-cell suspensions were then counted using a 
hemocytometer and used for flow cytometry and ex vivo stimulation assays. 
 
Ex vivo PMA/Ionomycin stimulation of lung cells 
 Whole lungs were isolated and digested using the collagenase digestion 
protocol and resuspended at 1 x 106/mL in stimulation media. Cell suspensions 
were added to 6-well cell culture-treated plates (Corning, Tewksbury, MA) so that 
each well contained 3 x 106 cells. Cells from each mouse were incubated 
separately in their own well. Phorbol 12-myristate 13-acetate (PMA) (LC 
Laboratories, Woburn, MA) was prepared by dissolving the lyophilized powder in 
DMSO and then diluting further in stimulation media so that a final concentration 
of 100 ng/mL was added to cell suspensions. Ionomycin (Sigma, St. Louis, MO) 
was diluted from the stock solution in stimulation media so that a final 
concentration of 1500 ng/mL was used to stimulate the cells. After 1 hour of 
stimulation at 37°C with 5% CO2 GolgiStop (BD Biosciences, San Jose, CA) was 
added to each well according to the manufacturer’s recommendations, and the 
stimulation continued for 5 additional hours. At the end of the 6 hour stimulation 
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the cells were collected and counted in preparation for intracellular cytokine 
staining (ICS).  
 
Ex vivo stimulation of lung CD4+T cells with killed pneumococcus 
Left lobes of specified treatment groups were harvested (3 mice each 
group) and digested according to the collagenase digestion protocol above. Cells 
were counted and pooled so that both groups contained the cells from 3 mice. 
CD4+ cells were positively selected using the EasySep positive selection kit for 
mouse CD4 cells (StemCell Technologies, Vancouver BC, Canada) according to 
the manufacturer’s instructions.  
Supernatant harvest after stimulation 
Concurrently, three spleens were harvested from naïve wildtype C57BL/6 
mice for use as the antigen presenting cells (APCs) in the stimulation assay. The 
pooled spleens were pushed through a 70 µm cell strainer in order to create a 
single cell suspension, washed with complete RPMI-1640 media, and pelleted by 
centrifugation. Red blood cells were lysed by resuspending the pelleted cells in 3 
mL red blood cell lysis buffer (Sigma, St. Louis, MO) for 2 minutes at room 
temperature. To stop the lysis 20 mL PBS was added and cells were pelleted 
again by centrifugation. The majority (4/5ths) of the cells were then pulsed with 
killed-Sp3 (kSp3) at a ratio of 3:1 (bacteria:cells) in 3 mL of stimulation media at 
37°C with 5% CO2 for 1 hour with gentle agitation every 20 minutes. The 
remaining fraction (1/5th) of the splenocytes were vehicle-pulsed (no killed Sp3) 
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for the unstimulated control wells by adding the same volume ratio to 2 mL of 
stimulation media. Following the antigen pulse, splenocytes were washed with 
stimulation media, counted, and resuspended in stimulation media at a 
concentration of 25 x 106/mL in a 50 mL conical tube. To prevent splenocyte 
proliferation, mitomycin C (Fisher Scientific, Waltham, MA) was added to the cell 
suspension at a final concentration of 50 µg/mL for 20 minutes at 37°C with 5% 
CO2. Cells were then washed three times with 25 mL stimulation media, counted, 
and resuspended so that 1.25 x 106 pulsed splenocytes were added to each well 
along with 1.25 x 105 CD4+ cells (10:1, splenocytes:CD4+ cells) in a total volume 
of 500 µL in a 48-well plate (Corning). 
CD4+ selected cells used for positive controls were stimulated with 10 uL 
per well of mouse T-activator α-CD3/CD28  Dynabeads® (Life Technologies, 
Carlsbad, CA) at approximately a 3:1 (beads:cell) ratio. Purified anti-mouse 
MHC-II clone M5/114.15.2 and isotype control clone RTK4530 (Biolegend, San 
Diego, CA) were added to appropriate wells at a concentration of 10 µg/mL to 
block MHC-II antigen presentation or as a control, respectively. Co-cultures were 
incubated for 72 hours, after which supernatants were collected and stored at -
80°C for multi-plex protein analysis.  
Preparation for Intracellular Cytokine Staining (ICS) 
For ICS assays following pneumococcus-specific stimulation cells were 
processed as stated above. Splenocytes used as APCs possessed the 
differential pan leukocyte marker CD45.1 so that they could be distinguished 
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from the treatment groups of CD4+ selected cells that possessed the typical 
CD45.2 allele during flow cytometric analysis. Co-cultures contained 5 x 106 
pulsed splenocytes and 5 x 105 CD4+ cells (10:1) plus α-CD3/CD28 T cell 
activator beads or MHC-II blocking antibody (or isotype control) where 
appropriate in a total volume of 1 mL per well in a 24-well plate (Corning). A 
protein transport inhibitor, GolgiStop, was added for the entire 12 hour 
incubation. Following the incubation. cells were harvested for ICS and flow 
cytometry.  
 
Flow Cytometry 
 Single cell suspensions were prepared as described above and stained 
with specified fluorescent antibodies in FACS buffer (see common buffers). All 
staining was performed on ice in the dark for 30 minutes. Stained cells were 
analyzed using a LSR-II (BD Bioscience, San Jose, CA) and the data were 
analyzed using FlowJo software (Tree Star Inc., Ashland, OR). 
Intracellular Cytokine Staining (ICS) 
ICS was performed using the BD Cytofix/Cytoperm 
Fixation/Permeabilization kit according to manufacturer’s instructions (BD 
Biosciences, San Jose, CA).The cytokine panels used in each of the three 
experiments in which ICS was performed are listed in Tables 2-4.  
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Table 2: Whole lung PMA/Ion stimulation ICS Cytokine Panel 
Cell Marker Fluorophore Clone Company 
CD45 PerCp-Cy5.5 30-F11 Biolegend 
CD4 PE GK1.5 eBioscience 
IL-17A APC eBio17B7 eBioscience 
IFN-γ FITC XMG1.2 eBioscience 
 
 
Table 3: Ex vivo CD4+ T cell stimulation ICS Cytokine Panel 
Cell Marker Fluorophore Clone Company 
Live/dead eFluor506 N/A eBioscience 
CD45.1 PE/Cy7 A20 Biolegend 
CD45.2 BV421 104 Biolegend 
CD3ε APC/Cy7 145-2C11 Biolegend 
CD4 APC RM4-4 Biolegend 
IL-17A PEeFluor610 17B7 eBioscience 
IFN-γ FITC XMG1.2 eBioscience 
IL-22 PE 1H8PWSR eBioscience 
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Table 4: Ipsilateral vs. Contralateral PMA/Ion stimulation ICS Cytokine 
Panel 
Cell Marker Fluorophore Clone Company 
CD45 PE/Cy7 30-F11 Biolegend 
CD3ε APC/Cy7 145-2C11 Biolegend 
CD4 APC GK1.5 eBioscience 
IL-17A PEeFluor610 17B7 eBioscience 
IFN-γ FITC XMG1.2 eBioscience 
 
Lung-Resident Memory Cells 
 Left (ipsilateral) and right (contralateral) lobes of uninfected mice were 
digested separately using collagenase (see above). Single-cell suspensions were 
prepared for flow cytometry and labeled with the antibodies in Table 5. Cells 
considered lung-resident memory CD4+ T cells were L/D-
/CD45+/CD3+/CD4+/CD11ahi/CD69+/CD62Llo/CD44hi. 
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Table 5: Lung-Resident Memory Cytokine Panel 
Marker Fluorophore Clone Company 
Live/dead 7AAD N/A BD Biosciences 
CD45 BV510 30-F11 Biolegend 
CD3ε APC/Cy7 145-2C11 Biolegend 
CD4 PE/Cy7 GK1.5 Biolegend 
CD11a APC M17/4 Biolegend 
CD69 PE H1.2F3 Biolegend 
CD62L FITC MEL-14 Biolegend 
CD44 PEeFluor610 IM7 Biolegend 
 
CD4+ Depletion and IL-17A neutralization assays 
For CD4+ depletion studies mice were treated with an anti-CD4+ 
monoclonal antibody (clone GK1.5) or a rat IgG2b isotype control antibody 
(BioXcell, West Lebanon, NH). Antibodies were diluted in sterile saline and 
administered with both i.p. and i.n. administrations, in which 500 µg and 100 µg 
of antibody were given, respectively, 72 and 24 hours prior to the pneumonia 
challenge. Mice were euthanized after 24 hours of pneumonia and bacterial 
burden in the lungs and blood was determined. 
 For IL-17A neutralization mice were treated with rat anti-mouse IL-17A 
(clone TC11-18H10) or rat IgG1 κ isotype control (clone R3-34) 18 hours before 
and 6 hours after the i.t. pneumonia challenge (BD Biosciences). The pre-
pneumonia anti-IL-17A treatment was administered both i.p. (100 µg in 100 µL) 
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and i.n. (20 µg in 20 µL). The post-pneumonia antibody treatment was an i.p. 
injection of 100 µg of antibody. Mice were euthanized after 24 hours of 
pneumonia, and bacterial burden in the lungs and blood was determined. 
 
Whole-Cell Pneumococcal ELISA 
 Pneumococcal-reactive IgG was measured in plasma. Sp3 and Sp19F 
were grown overnight on blood agar plates and suspended in sterile PBS so that 
1 x 107 CFU of each serotype was added in 50 µL to separate wells in a 96-well 
Nunc MaxiSorp plate (ThermoFisher Scientific). Plates were coated with 
pneumococcus overnight at 4°C. The following morning the plate was washed 
with ELISA wash buffer (see common buffers) and blocked with 100 µL per well 
of 1% bovine serum albumin (BSA) in PBS for 2 hours at room temperature. The 
plate was washed again and 50 µL of diluted plasma or lung homogenate sample 
was added to appropriate wells and incubated at room temperature for 2 hours. 
After washing, anti-mouse IgG- horseradish peroxidase (HRP) antibody (R&D 
Systems) was diluted 1:2000 in 1% BSA and 100 uL was added per well. The 
anti-mouse IgG-HRP was incubated at room temperature in the dark for 2 hours. 
The plate was again washed and developed using 3,3',5,5'-tetramethylbenzidine 
(TMB) substrate (R&D Systems). The reaction was stopped with 2N sulfuric acid 
stop solution (R&D Systems). The optical density of each well was determined 
immediately using a microplate reader set to 450 nm. 
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Whole Lung RNA Isolation 
 Whole lungs were collected after 24 hours of pneumonia and snap frozen 
until RNA extraction. RNA was extracted using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Whole lungs were 
homogenized in buffer RLT with 3.2 mm stainless steel beads in a Bullet Blender. 
Final RNA concentrations were measured on a NanoDrop 2000 (ThermoFisher 
Scientific). 
 
Deep Sequencing of Whole Lung RNA 
 Whole lung RNA from 3 mice was pooled in each group, saline and Het 
Imm, to form an n of one. A cDNA library was created using the NEBNext Ultra 
Directional Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA). 
Single-end 50 base pair read length sequencing was performed on an Illumina 
HiSeq 2500. Sequenced reads were aligned to the mm9 mouse genome. 
Analysis was done using a Globus Genomics pipeline hosted on the Galaxy 
platform.  
 
Plasma Transfer 
 Pooled plasma from each group, saline and Het Imm, was mixed with 
sterile PBS to make a 20% plasma solution. The solutions were filtered through a 
0.2 µm syringe-top filter. Sp3 was added to each group so that the final dose was 
5 x 104 CFU in 50 µL. The bacteria/plasma mixture was rotated in a 
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microcentrifuge (Eppendorf, Hamburg, Germany) tube at 4°C for 30 minutes with 
rotation. 50 µL of the bacteria/plasma mixture was instilled i.t. into each mouse. 
Bacterial burden in the lungs and blood was measured after 24 hours.  
 
Common Buffers and Solutions 
Lactated Ringer’s solution (LR)  
102 mM Sodium Chloride, 28 mM Sodium Lactate, 1.5 mM Calcium Chloride, 
and 4 mM Potassium Chloride 
Stimulation media 
RPMI-1640 media containing 10% fetal bovine serum (FBS), penicillin (100 
U/mL)/streptomycin (100 µg/mL), 1mM sodium pyruvate, 0.2 µM 2-
mercaptoethanol, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 10 
mM HEPES buffer 
Complete RPMI 
RPMI-1640 media containing 10% (FBS), penicillin (100 U/mL)/streptomycin (100 
µg/mL) 
FACS buffer for Flow Cytometry 
PBS (pH 7.4) containing 0.5% FBS, 2 mM Ethylenediaminetetraacetic acid 
(EDTA), sterile filtered (0.2 µm) 
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ELISA wash buffer 
0.05% Tween® 20 (Sigma, St. Louis, MO) in PBS pH 7.4  
 
Statistical Analysis 
Each graph represents at least two independent experiments, unless 
otherwise stated. All statistical analyses were done using GraphPad Prism 6.0 
(GraphPad). CFU data are expressed as individual values with medians, while 
the remaining data are shown as means with SEM. Two groups were compared 
using either the Student’s t test or Mann-Whitney U test. Multiple groups were 
compared using a one- or two-way analysis of variance (ANOVA) followed by the 
specific post hoc tests for multiple comparisons. Data were considered significant 
if p < 0.05 for all experiments.  
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CHAPTER THREE: LUNG-LOCALIZED TRM GENERATED BY SERIAL 
INFECTIONS WITH PNEUMOCOCCUS PROTECTS AGAINST HETEROTYPIC 
PNEUMONIA WHEN THE TWO ARE CO-LOCALIZED IN THE LUNG 
 
Rationale 
 Pneumococcal carriage decreases during the first 2 years of life due in 
part to the development of naturally acquired adaptive immune memory (Malley, 
2010). Humans have heterotypic memory T cells and serum antibodies that 
recognize diverse strains of influenza virus (McMichael et al., 1983; Sridhar et al., 
2013; Wilkinson et al., 2012). Both epidemiologic and experimental evidence in 
mice and in humans demonstrates that this naturally acquired heterotypic 
immunological memory provides substantial protection against respiratory 
infection with newly encountered influenza viruses (Braciale et al., 2012; Sridhar 
et al., 2013; Strutt et al., 2013; Wilkinson et al., 2012). Humans also have 
heterotypic CD4+ memory T cells and serum antibodies that recognize multiple 
serotypes of pneumococcus (Giefing et al., 2008; Lundgren et al., 2012; Wright 
et al., 2013). To our knowledge, the degree to which naturally acquired 
heterotypic antibodies and CD4+ T cells protect the lung against pneumococcal 
infection has yet to be examined.  
In addition to systemic immune responses, mucosal surfaces also contain 
resident memory T cells (TRM) that are elicited by viral infections (Clark, 2015; 
Mueller et al., 2013). The first evidence of TRM cells in the lung came from mouse 
studies of influenza infection that resulted in lung-localized, non-circulating 
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influenza-specific memory CD4+ T cells that provided superior defense against 
subsequent infections compared to the circulating influenza-specific central 
memory CD4+ T cells (Masopust et al., 2001; Teijaro et al., 2011; Turner et al., 
2014). Adult human lungs contain large numbers of CD4+ TRM cells based on 
surface staining with CD69, and at least some of these cells respond to influenza 
(Purwar et al., 2011; Sathaliyawala et al., 2013). These data suggested that prior 
respiratory infections induced a seeding of the lungs with TRM cells (Purwar et al., 
2011; Sathaliyawala et al., 2013). Upon phorbol ester stimulation, lung CD4+ TRM 
cells produced a variety of effector cytokines (Purwar et al., 2011; Sathaliyawala 
et al., 2013), which perhaps reflected diverse specificities and functions. Whether 
and how bacterial infections elicit or are influenced by lung CD4+ TRM cells is, to 
our knowledge, completely unexplored to date. In this study we examined cell-
mediated adaptive recall responses in the lungs using a model of naturally-
acquired heterotypic protection against pneumococcal pneumonia. 
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Results 
3.1 Serial respiratory infections establish heterotypic protection against 
pneumococcal pneumonia 
In order to advance our understanding of the immune mechanisms 
protecting normal healthy adults from pneumococcal pneumonia, we endeavored 
to model naturally-acquired heterotypic lung immunity in mice. We caused mild 
and self-limiting respiratory infections with pneumococcus, allowed 4-8 weeks for 
any inflammation to subside, and then infected the lungs of these mice with Sp3, 
a serotype to which they had not previously been exposed. In naïve mice, Sp3 
infection causes a severe pneumonia, which includes uncontrolled growth of the 
bacteria in the lungs and disseminated extrapulmonary infection (Jones et al., 
2005; Winter et al., 2009; Yang et al., 2015). The initial infections were performed 
with live pneumococcus via an intranasal (i.n.) instillation to mimic a natural 
infection, using a volume and delivery designed to distribute throughout the 
upper and lower airways of the mice. When mice were infected i.n. with one dose 
of Sp19F 4 weeks prior to Sp3 pneumonia challenge, the bacterial burden in the 
lungs of the mice did not differ significantly from the bacterial burden in the lungs 
of the control mice treated with sterile saline (Figure 2A). However, when mice 
were infected i.n. with two doses of Sp19F, one week apart, prior to the i.t. Sp3 
challenge, there was a multi-log reduction in lung bacterial burden compared to 
the saline-treated control group (Figure 2A). During early childhood, multiple 
different pneumococcal serotypes infect the airways and potentially generate 
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immune responses (Kadioglu et al., 2008; Salt et al., 2007). We tested whether 
diversified pneumococcal serotypes were similarly capable of providing 
heterotypic immune protection against pneumonia. Serial i.n. infections with 
Sp19F followed by Sp35B or with Sp19F followed by Sp35B followed by Sp23A 
were each capable of improving pulmonary defense against a heterotypic 
pneumococcus compared to control mice that received sterile saline previously 
instead of pneumococcus (Figure 2A). Bacteremia was also assessed, and mice 
that received serial pneumococcal exposures had significantly less Sp3 in their 
blood than did control mice previously receiving saline (Figure 2B). These data 
indicate that prior pneumococcal exposures elicit immune memory that can 
control and contain a highly virulent pneumococcus after respiratory infection. 
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Figure 2: Serial pneumococcal infections protect against subsequent 
pneumococcal pneumonia. 
 
C57BL/6 mice were infected with the specified pneumococcal serotypes (or 
saline) either one, two, or three times intranasally (i.n.) with doses of 1-3 x 106  
CFU each that were separated by 1 week. After a 4 week rest period mice were 
challenged intratracheally with 1x 106 CFU of Sp3 for 24h and lung (A) and blood 
(B) bacterial burden were determined. Each individual dot represents a single 
mouse and horizontal lines represent medians. Data are expressed as CFU per 
lung or mL of blood. Significance was assessed by 1-way ANOVA followed by 
Dunn’s post hoc test. *p < 0.05 for significant differences between the specified 
groups. 
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In order to determine whether this heterotypic protection was durable and 
life-saving, we followed cohorts of mice for a longer period of 7 days after Sp3 
infection. The saline treated mice began to decline around day 2 of pneumonia, 
with no mice living by day 5 (Figure 3). In contrast, 94% of the previously 
exposed (Het Imm) mice survived to the end of the experiment on day 7 (Figure 
3), at which point they were sacrificed so that lung and blood bacterial burdens 
could be determined. No Sp3 colonies were recovered from the lungs or blood of 
nearly all (16/17) mice that had been previously exposed to heterotypic 
pneumococci. The only mouse with an ongoing infection had less than 4x103 
CFU Sp3 remaining in its lungs, which represented ~99% clearance of the initial 
infection dose. These data demonstrate that heterotypic lung protection 
generated by mixed exposures to pneumococci can result in long-term, sterilizing 
immunity leading to a full recovery from an otherwise lethal infection. 
While our goal was to generate a mouse model of naturally acquired, 
heterotypic anti-pneumococcal pulmonary immunity, there was the potential the 
respiratory exposures to pneumococcus could bolster non-specific innate 
immune responses in the lung. In particular, although more transient than the 
protection observed here (lasting days instead of weeks or months), it has been 
previously demonstrated that intrapulmonary delivery of non-viable extracts from 
Haemophilus influenzae bacteria can remodel lung innate immune responses to 
provide improved host defense (Evans et al., 2010). This improved host defense 
was effective against a wide range of microbes including Gram-positive bacteria, 
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Gram-negative bacteria, viruses, and fungi (Evans et al., 2010). Therefore, we 
tested whether our pneumococcus-elicited defense against lung infection with 
heterotypic pneumococci could be stimulated by dead pneumococci, and 
whether the protective immunity elicited by respiratory pneumococcal infections 
extended to bacterial species other than pneumococcus. We did not see the 
same heterotypic protection against Sp3 pneumonia when mice were treated 
with equivalent numbers of Sp19F that were heat-killed instead of living (Figure 
4A). These data suggest that elements of active infection are essential to the 
generation of heterotypic immunity in the respiratory tract. Furthermore, prior 
infections with live pneumococci did not provide lung protection against the 
unrelated Klebsiella pneumoniae in the lungs (Figure 4B). These data suggest 
that pneumococcal infections generate protection against pneumonia that is 
restricted in microbial specificity. Altogether, these results argue against the 
respiratory exposures to pneumococcus remodeling pulmonary innate immunity 
to protect against most or all pathogens, but suggest instead that repeated 
respiratory infections with pneumococci generate new mechanisms of lung 
defense that are heterotypic but pneumococcus-specific. 
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Figure 3: Repeated pneumococcal infections provide long-lasting, 
sterilizing protection against pneumonia. 
 
Mice previously infected i.n. with Sp19F, Sp35B, and Sp23A or saline were 
infected 4 weeks later with 3 x 105 CFU Sp3 i.t. Survival was monitored over 7 
days (Kaplan-Meier curve, n= 9-10). Significance was determined using a 
Mantel-Cox test. The curves were considered significantly different if p < 0.05 (*). 
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Figure 4: Live infections are required for heterotypic lung protection.  
 
(A) C57BL/6 mice were administered 2 doses of 1 x 106 CFU of heat-killed 
Sp19F or saline by intranasal instillation. 4 weeks later they were challenged with 
1 x 106 CFU i.t. Sp3 for 24h after which lung bacterial burden was determined. 
(B) Het Imm or saline-treated mice were infected with 5 x104 CFU i.t. Klebsiella 
pneumoniae and lung bacterial burden was assessed after 24h. Each individual 
dot represents a single mouse and horizontal lines represent medians. Data are 
expressed as CFU per lung or milliliter of blood. Significance was assessed using 
a Mann-Whitney U test. *p < 0.05 
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3.2 Heterotypic anti-pneumococcal immunity accelerates lung neutrophil 
recruitment 
 To gain a first glimpse into the mechanisms behind heterotypic lung 
protection during pneumococcal pneumonia, we began by examining histological 
views of susceptible and resistant lungs, both with and without Sp3 pneumonia. 
One mechanism by which viral infections have been demonstrated to remodel 
adaptive immunity and protect against viral pneumonia is via the generation of 
inducible bronchus-associated lymphoid tissues (iBALT), characterized by 
organized lymphoid aggregates in the sub-epithelium and airway interstitium 
(Moyron-Quiroz et al., 2004). However, H&E staining did not reveal iBALT, other 
types of tertiary lymphoid organs, or any observable histological differences 
between non-pneumonic lungs of mice with heterotypic immunity compared to 
those of saline control mice (Figure 5). After 24 hours of infection with Sp3, both 
types of lungs showed histological evidence of acute pneumonia, including 
leukocyte recruitment to the air spaces and interstitia (Figure 5). To quantify the 
airspace recruitment of leukocytes, bronchoalveolar lavage (BAL) was performed 
7 and 24 hours post Sp3 infection. After 7 hours, there were significantly more 
neutrophils in the airspaces of the protected lungs compared to susceptible 
controls (Figure 6A). At 24 hours, by which time there were multi-log decreases 
in bacteria in the lungs of mice with heterotypic protection, there were no longer 
differences in the numbers of airspace neutrophils (Figure 6A), perhaps due to 
the reduction in bacterial stimuli that were present by that time. There was no 
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difference in airspace macrophage numbers between control and protected lungs 
at either time point (Figure 6B). Thus, prior respiratory infections with 
pneumococcus remodel the lung immune response to accelerate neutrophil 
recruitment. 
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Figure 5: Het Imm lungs do not contain obvious iBALT. 
 
Representative H&E images of Het Imm or saline-treated mouse lungs that were 
fixed with 4% PFA and embedded in paraffin. Mice were infected with 1 x 106 
CFU i.t. Sp3 for 24h (pneumonic). The magnification is indicated in the upper left 
corner of the images. 
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Figure 6: Heterotypic anti-pneumococcal immunity accelerates lung 
neutrophil recruitment. 
 
BALF was collected from Het Imm and saline lungs 7 and 24h after infection with 
1 x 106 CFU i.t. Sp3. Cells were collected and cytospin was performed to 
determine cell differential counts (n= 8-9). Data are expressed as total number of 
neutrophils (A) and macrophages (B). Bars represent means with standard error 
of the mean (SEM) displayed. Data were log-transformed (Y=Log(Y)) and 
significance was assessed by 2-way ANOVA followed by Sidak’s post hoc test. 
*p < 0.05 for significant differences between the specified groups. 
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3.3 Increased lung-to-neutrophil signaling due to heterotypic immunity 
 Because neutrophil recruitment was accelerated, we examined the 
expression of neutrophil-targeting cytokines in the lungs. The complexity of the 
lung is demonstrated in part by the large variety of cell types that collaborate to 
maintain structure, function, and immune defense. During pneumococcal 
pneumonia, various neutrophil-directed cytokines have been shown to come from 
distinct cellular sources (Pittet et al., 2011; Yamamoto et al., 2012). In the 
airspaces of mice previously exposed to pneumococcus the epithelial-derived 
neutrophil chemotactic factors CXCL5 and GM-CSF (Yamamoto et al., 2012), the 
myeloid cell-derived CXCL2 (but not proinflammatory cytokine TNFα) (Pittet et 
al., 2011), and CXCL1 and G-CSF produced by other structural cells (Yamamoto 
et al., 2012) were significantly increased after 7 hours of Sp3 pneumonia 
compared to control mice (Figure 7A-F). After 24 hours of Sp3 pneumonia these 
differences were no longer apparent, likely due to the diminished bacterial 
burden in the lungs of protected mice. These data suggest that during 
pneumococcal pneumonia in heterotypic immune lungs, multiple groups of cells 
that make up the lung are stimulated to produce higher levels of neutrophil-
recruiting cytokines. 
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Figure 7: Increased lung-to-neutrophil signaling due to heterotypic 
immunity. 
 
(A-F) Het Imm and saline-treated control mice were challenged with 1 x 106 CFU 
i.t. Sp3 and BALF was collected at 7 (n= 14) and 24h (n= 4). Cytokines were 
measured in the BALF using a multi-plex Luminex assay. Data are expressed as 
pg/mL and bars represent means with SEM. Dashed lines indicate the limit of 
detection for the particular analyte. Significance was assessed by 2-way ANOVA 
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followed by Sidak’s post hoc test. *p < 0.05 for significant differences between 
the specified groups. 
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3.4 CD4+ Th17 cells in lungs with heterotypic immunity during pneumococcal 
pneumonia  
 The proinflammatory cytokine IL-17, primarily produced by CD4+ T helper 
cells (Th17), has been shown to be an important factor in host defense at 
mucosal surfaces (Aujla et al., 2007; Chen et al., 2011). A major effector function 
of IL-17 is the stimulation of epithelial and stromal cells to produce cytokines that 
induce the emigration of neutrophils into mucosal sites (Aujla et al., 2007; Kolls 
and Linden, 2004). Due to the increase in various neutrophil chemotactic factors 
in the airspaces of mice with heterotypic protection, we wanted to examine the 
Th17 signal in the lungs of pneumonic naïve and Het Imm mice. We were not 
able to detect any appreciable IL-17A (less than 17 pg/mL) or IL-23p19 (less than 
20 pg/mL), a stabilization factor for Th17 responses, in the BALF of either 
treatment group (Korn et al., 2009). It is understandable that the concentration of 
IL-17A was undetectable in the airspaces of the lung due to evidence that CD4+ 
T cells typically are found in the lung parenchymal tissue more than in the 
airspaces (Purwar et al., 2011; Teijaro et al., 2011). Therefore, IL-17A protein 
was measured in whole lung homogenates. Pneumonic lungs from mice with 
heterotypic immunity contained significantly more IL-17A protein than those from 
pneumonic naïve mice (Figure 8A). IFN-γ can also enhance neutrophil-mediated 
defenses against pneumococcus in the lungs, and like IL-17A can come from 
memory T cells, but there was no difference in IFN-γ in pneumonic lungs due to 
heterotypic immunity (Schroder et al., 2004; Yamada et al., 2011) (Figure 8B). 
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Other hallmarks of lung inflammation due to pneumococcal infection were 
unchanged (TNFα and CXCL1) or significantly reduced (G-CSF) in heterotypic 
lungs compared to control (Figure 8C), highlighting the differential immune 
kinetics in protected and naive lungs. IL-17A can be generated from multiple 
cellular types, so we tested whether heterotypic immunity caused pneumonic 
lungs to contain more Th17 cells specifically. Single cell suspensions of 
pneumonic lungs were stimulated with PMA/Ionomycin plus golgi blockade to 
allow for intracellular cytokine staining. While the percentage of Th1 (defined as 
CD4+ IFN-γ+) cells did not change in pneumonic lungs due to previous 
pneumococcal exposures, the percentage of Th17 (CD4+ IL-17A+) cells was 
substantially greater in lungs with heterotypic immunity (Figure 9A). This 
impacted the overall abundance of these cytokine-secreting T cells, with the total 
number of Th1 cells unchanged due to prior serial exposures to pneumococci but 
significant increases in Th17 cells during active heterotypic protection (Figure 9B-
C). Thus, during pneumonia, lungs with heterotypic immunity contain more Th17 
cells and IL-17A than do lungs of mice which had never previously had 
pneumococcal respiratory infections. 
  
  
77 
 
 
Figure 8: Elevated IL-17A protein expression in Het Imm lungs  
 
(A-C) Het Imm and saline control mice were challenged with 1 x 106 CFU Sp3 i.t. 
for 24h. Cytokine protein concentrations were measured in whole lung 
homogenates by ELISA. Data are expressed as pg/lung and bars represent 
means with SEM (n= 5-11). Dashed lines indicate the limit of detection for that 
assay. Significance was assessed using the Student’s t test. *p < 0.05 
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Figure 9: Pneumonic Het Imm lungs are enriched with Th17 cells. 
 
Het Imm and saline control mice were challenged with 1 x 106 CFU Sp3 i.t. for 
24h. Whole lungs were digested with collagenase and single cells were 
stimulated with PMA/Ionomycin for 6h in the presence of a protein transport 
inhibitor. IL-17A+ and IFN-γ+ CD4+ cells were detected using intracellular cytokine 
staining (ICS). (A) Representative flow cytometry plots from Het Imm and saline 
mice. (B-C) IL-17A+ and IFN-γ+ CD4+ cells were quantified and are displayed as 
number of cells per lung. Bars represent means with SEM (n= 6-7). Significance 
was assessed using the Student’s t test. *p < 0.05  
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3.5 CD4+ cells are required for maximum heterotypic protection  
 CD4+ Th17 cells can provide defense against pneumococcus if elicited by 
vaccines or by homotypic infection and they defend the lung against heterotypic 
Klebsiella infections when elicited by an experimental vaccine so they are strong 
candidates for mediating heterotypic lung protection against pneumococcus 
(Chen et al., 2011; Malley et al., 2006; Wilson et al., 2015). To test whether CD4+ 
cells made essential contributions to the lung protection afforded by heterotypic 
anti-pneumococcal immunity, we depleted CD4+ cells after full immunity had 
been established but immediately prior to the final Sp3 challenge. At 72 and 24 
hours before the Sp3 pneumonia challenge, mice with heterotypic immunity were 
administered either GK1.5 or IgG intranasally and intraperitoneally in order to 
ensure complete depletion of CD4+ cells (Kamei et al., 2011). Mice that received 
GK1.5 to deplete CD4+ cells had significantly more Sp3 CFU in their lungs 
compared to the mice treated with non-targeting IgG (Figure 10A). In addition, 
the depletion of CD4+ cells resulted in significantly less IL-17A and IFN-γ protein 
in the lungs of the GK1.5-treated mice compared to IgG controls (Figure 10B-C). 
These data indicate that CD4+ cells are critical sources of the increased IL-17A 
(and other potentially protective T helper cytokines) during pneumonia and make 
essential contributions to the improved lung defense of mice with naturally 
acquired heterotypic anti-pneumococcal immunity. 
  
  
80 
 
 
Figure 10: CD4+ cells are required for maximum heterotypic protection 
against pneumococcal pneumonia 
 
Mice were infected i.t. with Sp19F (twice, 1 week apart) and challenged 4 weeks 
later with 1 x 106 CFU i.t. Sp3. 72 and 24h prior to pneumonia challenge CD4+ 
cells were depleted with the GK1.5 antibody. (A) Lungs were harvested after 24h 
of pneumonia and lung bacterial burden was determined. Individual dots 
represent a single mouse and horizontal lines represent medians. The dashed 
line indicates the input CFU. Significance was assessed by a Mann Whitney U 
test. (B-C) IL-17A and IFN-γ protein levels were measured by ELISA in the whole 
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lung homogenates from (A). Data are expressed as pg/lung. Bars represent 
means with SEM (n= 8-9). Significance was assessed using the Student’s t test. 
*p < 0.05 
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3.6 Recovery from respiratory infection seeds the lungs with pneumococcus-
specific Th17 and Th1 cells 
 The nature and activities of pneumococcus-specific memory CD4+ T cells 
elicited by respiratory infections are unknown. Because healthy normal human 
lungs contain resident memory T cells and mice who recover from influenza 
infection have lungs containing influenza-specific CD4+ TRM cells, we 
hypothesized that recovery from respiratory infections with pneumococcus may 
leave behind a population of pneumococcus-specific CD4+ T cells in the lungs, 
poised to respond to subsequent infections with the production of protective 
cytokines (Hogan et al., 2001b; Purwar et al., 2011; Sathaliyawala et al., 2013; 
Teijaro et al., 2011). Therefore, we investigated pneumococcus-specific CD4+ T 
cells from healthy lungs without an infectious stimulus. We collected CD4+ cells 
from the healthy and histologically normal (Figure 5) lungs of mice with or without 
heterotypic immunity, and stimulated these cells with pneumococcus-pulsed 
antigen-presenting cells (APCs) to assess reactivity. To monitor cell-specific 
expression of cytokines that defend the lungs, we used intracellular cytokine 
staining (ICS) to measure IL-17A and IFN-γ in CD4+ T cells. The cell gating 
strategy for these experiments is shown in figure 11. Non-specific stimulation of 
the T cells using anti-CD3/anti-CD28 activating beads demonstrated that both 
types of lungs contained CD4+ T cells that were capable of producing these 
cytokines (Figure 12, left), consistent with prior analyses of mouse and human 
lungs (Sathaliyawala et al., 2013; Turner et al., 2014). Neither cytokine was 
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produced by CD4+ T cells from either type of lung when they were cultured with 
vehicle-pulsed APCs (Figure 12, middle). Importantly, both IL-17A and IFN-γ 
were expressed by CD4+ T cells from Het Imm lungs that were cultured with 
pneumococcus-pulsed APCs (Figure 12, right). IL-22, another product of Th17 
cells, was also measured but no positive cells were observed in any sample 
(Aujla et al., 2007).These data demonstrate for the first time that pneumococcus-
specific CD4+ T cells are in the lungs of mice with heterotypic immunity, even 
without an ongoing infection. Of interest, these cells are not polyfunctional with 
regard to the 3 cytokines analyzed, but instead appear to separate into distinct 
sets with Th1-like or Th17-like properties. 
 We next sought to determine whether other cytokines that are hallmarks of 
T cell activation may also be expressed by pneumococcus-specific CD4+ T cells, 
in addition to IL-17A and IFN-γ. To answer this question, cultures of lung CD4+ T 
cells plus APCs, which were pulsed with vehicle or pneumococcus, were 
incubated for 72 hours after which supernatants were analyzed for the presence 
of T helper cell effector cytokines. A blocking antibody against MHC-II was used 
to test whether antigen presentation to CD4+ T cells was specifically essential to 
the cytokine responses. Figures 13A and B show the results from CD4+ T cells 
cultured with vehicle-pulsed APCs (unstimulated), pneumococcus-pulsed APCs, 
pneumococcus-pulsed APCs plus MHC-II blockade, or anti-CD3/anti-CD28 as a 
positive control. Lung CD4+ cells from mice without heterotypic immunity were 
functionally capable of making cytokines as evidenced by the anti-CD3/anti-
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CD28 stimulation, but they produced none of these cytokines after incubation 
with pneumococcus-pulsed APCs (Figure 13B). In sharp contrast, CD4+ cells 
from the lungs of mice with heterotypic immunity produced multiple cytokines in 
response to pneumococcus-pulsed APCs, including IL-17A, IFN-γ, IL-22, IL-2, 
and TNF-α (Figure 13A). The induction of all of these cytokines was completely 
ablated by the MHC-II blocking antibody (Figure 13A), confirming that this 
cytokine expression resulted from antigen-specific MHC-II-dependent activation 
of CD4+ T cells. However, MHC-II-dependent activation of pneumococcus-
specific CD4+ cells from lungs with heterotypic immunity did not result in 
expression of either IL-4 or IL-10 (Figure 13A), demonstrating that T cells 
residing in the lungs after respiratory infections with pneumococcus have distinct 
T helper cell phenotypes. Overall, these results demonstrate that respiratory 
infections seed the lungs with pneumococcus-specific memory CD4+ T cells 
having Th17 and Th1 phenotypes. In order to evaluate the requirement of IL-17A 
during heterotypic lung protection, we pretreated Het Imm mice with either an 
anti-IL-17A neutralizing antibody or non-targeting IgG antibody both i.n. and i.p. 
18 hours before the Sp3 pneumonia challenge. Mice were given an additional 
injection of the respective antibodies 6 hours after the Sp3 pneumonia challenge. 
Lungs from both groups were harvested after 24 hours and lung bacterial burden 
was assessed. The neutralization of IL-17A, shown in figure 13C, caused a 
moderate yet non-statistically significant increase in lung Sp3 burden compared 
to the IgG control group. These results suggest that heterotypic lung protection 
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against pneumococcus does not depend solely on IL-17A and that other T helper 
cytokine products like IFN-γ may also contribute for full heterotypic protection. 
 
  
  
86 
 
 
Figure 11: Flow cytometry gating scheme for ex vivo CD4+ T cell 
pneumococcal stimulation. 
 
Left lung lobes from Het Imm and saline mice were digested with collagenase 
and CD4+ cells were positively selected and stimulated for 12h with antigen-
pulsed splenocytes. Intracellular cytokine staining was performed. 
Representative flow cytometry plots outlining the general cell gating strategy.   
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Figure 12: CD4+ T cells from uninfected heterotypic lungs display Th17 and 
Th1-like phenotypes. 
 
The left lobes of Het Imm and saline control mice were digested with collagenase 
and CD4+ cells were stimulated with killed Sp3-pulsed splenocytes for 12h in the 
presence of a protein transport inhibitor. Cells were collected and ICS was 
performed for IL-17A, IFN-γ, and IL-22. Flow cytometry plots show IL-17A and 
IFN-γ production from CD3+ cells in 3 groups: pan T cell activator α-CD3/CD28 
(positive control), vehicle-pulsed antigen presenting cells (APCs, negative 
control), and killed pneumococcus-pulsed APCs (APCs-PN).   
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Figure 13: Lung-resident, pneumococcus-specific CD4+ T cells produce 
multiple effector cytokines. 
 
The left lobes of Het Imm and saline control mice were digested with collagenase 
and CD4+ cells were stimulated with killed Sp3-pulsed splenocytes for 72h. 
Supernatants from Het Imm (A) and saline (B) stimulations were collected and T 
cell cytokines were measured using a multi-plex luminex assay. In addition to 
killed pneumococcus samples, three controls are displayed: vehicle-pulsed 
splenocytes (negative control), pan T cell activator α-CD3/CD28 (positive 
control), and α-MHC-II blocking antibody added to killed pneumococcus-
stimulated samples. IL-22 protein was measured independently using an ELISA. 
Cytokine concentrations were measured in 3 separate stimulation experiments 
and are displayed as pg/mL. Bars represent means with SEM. “LOD” above bars 
indicates the limit of detection for each analyte. Data were log transformed 
(Y=Log(Y)) and significance was assessed by 1-way ANOVA followed by a 
Dunnett’s post hoc test for multiple comparisons. *p < 0.05 for significant 
differences in relation to the APCs-vehicle sample for each cytokine. (C) Mice 
were infected i.t. with Sp19F (twice, 1 week apart) and challenged 4 weeks later 
with 1 x 106 CFU i.t. Sp3. Prior to the Sp3 challenge mice were treated i.p. and 
i.n. with anti-IL-17A or IgG control antibodies (18h before and 6h after). Lungs 
were harvested after 24h of pneumonia and lung bacterial burden was 
determined. Individual dots represent a single mouse and horizontal lines 
represent medians. The dashed line indicates the input CFU. Significance was 
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assessed using a Mann Whitney U test (left). IL-17A protein levels were 
measured by ELISA in the whole lung homogenates (right). Data are expressed 
as pg/lung. Bars represent means with SEM (n= 9-12). Significance was 
assessed using the Student’s t test. *p < 0.05 
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3.7 Heterotypic pulmonary defense and lung CD4+ TRM cells imprint locally 
 In addition to being non-circulating CD4+ T cells that reside in tissues, 
resident memory CD4+ T cells are defined by high cell surface expression of 
CD11a and CD69 in the inactivated state (Teijaro et al., 2011; Turner et al., 
2014). In mice, CD4+ TRM cells also have high expression of the memory marker 
CD44 and low expression of the lymphoid homing receptor CD62L (Teijaro et al., 
2011). We tested whether the resolution of respiratory infections with 
pneumococcus seeded the lungs with CD4+ TRM cells using these surface 
markers. In addition, since previous studies suggest that TRM cells disperse 
throughout the skin after a focused viral infection (Jiang et al., 2012), but nothing 
is known about regional localization of lung TRM cells, we examined lung CD4
+ 
TRM cells and heterotypic anti-pneumococcal defense in distinct lung regions. 
This is of particular interest for pneumococcal respiratory infections because 
these are most often concentrated in the upper airways (nasopharyngeal 
colonization) or in a single one of the 5 lung lobes when in the lower airways 
(lobar pneumonia). We modeled this in mice by generating pneumococcal 
infections in a single lung lobe, and then analyzing CD4+ TRM cells and integrated 
antibacterial defense in the same (ipsilateral) lung lobe compared to the 
previously uninfected contralateral lobes from the other side of the thoracic 
cavity. The flow plots showing CD11a vs. CD69 in figure 14 were previously 
gated on CD3+CD4+ leukocytes. The ipsilateral lobe showed clear evidence of 
lung CD4+ TRM cells with a distinct population of CD11a
high CD69+ cells appearing 
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in mice with heterotypic immunity, but not in those without (Figure 14A). These 
CD3+CD4+CD11ahiCD69+ cells from the lung were also CD44hi and CD62Llow 
(Figure 14A, right), further confirming the lung CD4+ TRM cell phenotype. These 
data demonstrate that pulmonary infections with pneumococcus generate lung 
CD4+ TRM cells. In striking contrast to the ipsilateral lobe, the contralateral lung 
lobes did not show accumulation of CD3+CD4+CD11ahiCD69+ cells (Figure 14A). 
Overall, we observed a higher percentage (of CD3+CD4+ cells) and total number 
of TRM cells in the ipsilateral lobes of mice previously infected with 
pneumococcus (Figure 14B, top) even though there was no change in the 
percentage or number of CD4+ T cells compared to control mice (Figure 14B, 
bottom). This leads to the unexpected conclusion that lung CD4+ TRM cells 
localize to and remain in the previously infected tissue site rather than distributing 
widely throughout the respiratory mucosa. The composition of cells from the 
spleen that were identified with these surface markers did not change between 
control and heterotypic mice (Figure 15). As expected, in both sets of mice there 
were very few CD3+CD4+ T cells that were CD11ahiCD69+ in the spleen 
(Figure15). The majority of the CD3+CD4+ cells in the spleens were characteristic 
of central memory T cells (TCM) with CD44
+CD62L+ staining (Figure 15)(Mueller 
et al., 2013). 
To determine whether IL-17A-producing CD4+ T cells were also 
differentially localized to the site of previous pneumococcal infections, cells from 
the left and right lung lobes of mice with or without heterotypic anti-
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pneumococcal immunity were analyzed by intracellular cytokine staining. A 
distinct population of IL-17A-producing cells was present only in the ipsilateral left 
lobes from mice with heterotypic immunity. We did not observe IL-17A-producing 
cells in either the left (ipsilateral) lobe of control mice or the right (contralateral) 
lobes of heterotypic mice (Figure 16A). This observation held true for all mice 
tested, as there was a significant increase in IL-17A-producing CD4+ T cells in 
the ipsilateral left lobes of heterotypic mice compared to control mice, while the 
frequency and number of IFN-γ-producing CD4+ T cells was unchanged (Figure 
16B). While previous literature has demonstrated a distribution of memory cells 
throughout a surface such as the skin following a viral infection (Jiang et al., 
2012), in our model lung TRM cells remain at the site of previous pneumococcal 
infections. If lung CD4+ TRM cells localize and are responsible for anti-
pneumococcal defense of the tissues, then pulmonary defense against severe 
pneumonia should also localize to the previously infected lung tissues. Studies 
described above revealed that both i.n. and i.t. infections with pneumococcus 
were capable of eliciting heterotypic anti-pneumococcal pulmonary defense. The 
former more diffusely distributes the bolus of bacteria throughout the respiratory 
tract including the upper airways and all 5 lung lobes, whereas the latter 
concentrates all of the infection to a single lung lobe. Both i.n. and i.t. 
pneumococcal exposures resulted in immune defenses that led to a significant 
reduction in lung Sp3 burden compared to saline control mice, with the more 
concentrated infections trending towards (but not reaching statistical significance) 
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even better protection (Figure 17). These data demonstrate that a natural route 
of infection with pneumococci accessing the lungs via the nasopharyngeal cavity 
can elicit lower reparatory tract protection. Given our findings that a strictly lobar 
pneumonia led to a lobe-specific accumulation of lung CD4+ TRM cells, we 
hypothesized that heterotypic protection against pneumococcus might also be 
restricted within the respiratory tract. In order to test whether the 
compartmentalization of lung TRM cells could impact heterotypic lung protection, 
we designed a unique animal model of infections and immunity. All mice were 
infected twice with Sp19F i.t. in their left lobe selectively separated by a week, 
and then after the typical rest time of 4-8 weeks one group was challenged with 
Sp3 i.t. in the ipsilateral (left) and the other group in the contralateral (right) lobes 
(Figure 18A). After 24 hours of lobar pneumonia (left or right), whole lungs were 
harvested and bacterial burdens were measured. We first determined whether 
anatomical or other differences between the left and right lobes of the mouse 
lung might impact lung defense in the absence of prior infections. The anatomical 
site of infection did not affect bacterial growth and Sp3 lung burdens were 
equivalently high in naïve mice whether the infection was in the left or right lobes 
(Figure 18B). In stark contrast, in mice which had recovered from prior 
heterotypic infections of the left lobe, infections of the same (ipsilateral) lobe led 
to significant decreases in bacterial burden compared to infections of the 
contralateral (right) lobes of mice with the same prior infections (Figure 18C). The 
previously infected lobe but not the contralateral lobes were capable of initiating 
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a rapid and robust heterotypic recall response that protected against further 
infection. We conclude that a localized pneumococcal infection in the lung results 
in the regional deposition of CD4+ TRM cells that protect the immediate but not 
distant respiratory mucosa against a subsequent heterotypic pneumococcal 
pneumonia. 
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Figure 14: Lung CD4+ TRM cells seed the site of previous pneumococcal 
infections, not the entire lung. 
 
Mice were infected i.t. with Sp19F (twice, 1 week apart) to generate heterotypic 
immunity. 4 weeks later the left (L) and right (R) lobes of uninfected Het Imm and 
saline control mice were digested separately with collagenase. (A) 
Representative flow cytometry plots showing lung TRM cells that were identified 
as CD3+/CD4+/CD11ahi/CD69+/CD62Llo/CD44hi. (B) CD4+ cells and TRM cells 
were quantified in the left (ipsilateral) and right (contralateral) lobes of Het Imm 
and saline mice (n= 4-5). Data are displayed as % CD11ahiCD69+ of CD4+ cells 
and total number of TRM cells. % CD4
+ cells (bottom) are of CD3+ cells. Bars 
represent means with SEM. Significance was assessed by 2-way ANOVA 
followed by Tukey’s post hoc test. *p < 0.05 for significant differences between 
the specified groups. 
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Figure 15: Markers of memory T cells in the spleen. 
 
Mice were infected i.t. with Sp19F (twice, 1 week apart) to generate heterotypic 
immunity. 4 weeks later spleens of uninfected Het Imm and saline control mice 
were harvested and single cell suspensions were created. Representative flow 
cytometry plots showing staining for TRM cells that were identified as 
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CD3+/CD4+/CD11ahi/CD69+ (top). Other markers of memory T cells CD44 and 
CD62L were also identified (bottom). 
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Figure 16: Lung resident Th17 cells localize to the site of previous 
pneumococcal infections.  
 
Mice were infected i.t. with Sp19F (twice, 1 week apart) to generate heterotypic 
immunity. 4 weeks later single cells from the ipsilateral (L) and contralateral (R) 
lobes of Het Imm and saline mice were stimulated with PMA/Ionomycin for 6h in 
the presence of a protein transport inhibitor. Cells were prepared for flow 
cytometry and ICS was performed to monitor cytokine production. (A) 
Representative flow plots show IL-17A and IFN-γ-producing CD4+ cells from Het 
Imm and saline lungs. (B) IL-17A (top) and IFN-γ-producing CD4+ cells (bottom) 
were quantified in the left (ipsilateral) and right (contralateral) lobes of Het Imm 
and saline mice (n= 5-6). Bars represent means with SEM. Significance was 
assessed by 2-way ANOVA followed by Tukey’s post hoc test. *p < 0.05 for 
significant differences between the specified groups. 
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Figure 17: A natural route of infection with pneumococci via the 
nasopharyngeal cavity can elicit lower respiratory tract protection. 
 
Mice on a mixed background were infected with two rounds of saline, i.n. Sp19F 
(Het Imm i.n.), or i.t. Sp19F (Het Imm i.t.). After 4 weeks they were challenged 
with 1 x 106 CFU Sp3 via i.t. instillation. Lungs were harvested after 24h of 
pneumonia and lung bacterial burden was determined. Individual dots represent 
a single mouse and horizontal lines represent medians. The dashed line 
indicates the input CFU. Data are expressed as CFU per lung. Significance was 
assessed by 1-way ANOVA followed by Dunn’s post hoc test. *p < 0.05 for 
significant differences between the specified groups. 
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Figure 18: Heterotypic pulmonary defense is compartmentalized within the 
lung. 
 
(A) Model of ipsilateral vs contralateral heterotypic pneumonia challenge. (B) The 
growth of Sp3 was assessed in the different lobes of naïve mice after 24h of 
pneumonia. (C) All mice received two i.t. Sp19F infections in their left lobes one 
week apart. Following the 4 week rest period, half of the mice were challenged 
with 1 x 106 Sp3 CFU in their ipsilateral (left) lobe, and the other half were 
challenged in their contralateral (right) lobes. Lung bacterial burden was 
determined after 24h of Sp3 pneumonia. Data are expressed as CFU per lung. 
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Individual dots represent a single mouse and horizontal lines represent medians. 
The dashed line indicates the input CFU. Significance was assessed using a 
Mann Whitney U test. *p < 0.05 
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CHAPTER FOUR: B CELL CONTRIBUTIONS TO PNEUMOCOCCAL 
HETEROTYPIC IMMUNITY 
 
Rationale 
 The importance of anti-polysaccharide capsule (PC) antibodies in 
combating pneumococcal disease has been demonstrated since the early 20th 
century when passive serotherapy was widely used until the introduction of 
antibiotics (Podolsky, 2005). Current vaccine strategies boost immune responses 
in order to target the PC, as it is considered the most important virulence factor of 
the pneumococcus. However, vaccination with purified polysaccharide, while 
effective against invasive pneumococcal disease in healthy adults, fails to 
generate immunologic memory and is not immunogenic in children under 2 years 
of age. Newer vaccines utilize highly immunogenic protein conjugates (T cell-
dependent antigens) that induce both humoral and cell-mediated immunity, but 
this approach still targets only the pneumococcal serotypes contained in the 
vaccine and have also been shown to induce serotype replacement of non-
vaccine serotypes (Yildirim et al., 2015).  
Immunization of mice with a whole-cell pneumococcal vaccine provided 
protection against nasopharyngeal colonization that was not dependent on anti-
pneumococcal antibodies, but rather on CD4+ T cells (Malley et al., 2006). 
However, protection from invasive pneumococcal disease that was induced by 
nasopharyngeal colonization with live pneumococcus was dependent on 
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antibody-mediated phagocytosis, not CD4+ T cells (Cohen et al., 2011). In order 
to develop more effective pneumococcal vaccines we need to better understand 
how cell-mediated and humoral immune responses cooperate in protected 
individuals. Naturally-acquired immunity against pneumococcus likely requires 
adaptive immune responses that provide heterotypic protection against the >90 
pneumococcal serotypes. Common cell wall components such as protein 
elements that are present in all pneumococci are the major candidates that 
stimulate this cross-serotype protection. It is unclear what role heterotypic anti-
pneumococcal antibodies play in the protection against pneumococcal disease 
following natural exposures. Using the model of heterotypic immunity described 
above, we began to address the contributions of B cells and anti-pneumococcal 
antibodies that were generated following serial exposures to pneumococci. 
  
  
107 
Results 
4.1 B cell-related gene signatures are highly enriched in pneumonic lungs 
previously exposed to pneumococci 
 The data in chapter 3 highlighted the critical role that CD4+ T helper cells 
play in heterotypic protection against pneumococcal pneumonia in a model of 
naturally-acquired immunity. In an effort to gain a wider view of the 
immunological gene signatures that may be enriched in the lungs of protected 
mice compared to susceptible mice following resolution of pneumococcal 
infections, a genome-wide transcriptome analysis was performed on the 
pneumonic whole lungs of mice from each group using the Illumina sequencing 
platform. The top 25 genes that were upregulated in the lungs of Het Imm mice 
compared to saline lungs are shown in figure 19. While we did observe 
upregulation in T helper cell related genes like Cd4 and Lat (Linker for activation 
of T cells family member 1), the presence of a large number of B cell-related 
genes was especially striking (Figure 19). The most highly induced genes 
included various B cell immunoglobulin genes such as Igkc, Ighm, and Ighg2c in 
addition to an important B cell chemoattractant Cxcl13, which plays a role in 
follicle organization in lymphoid tissues (Ansel et al., 2000) (Figure 19). When we 
examined the concentration of CXCL13 protein at baseline (non-pneumonic) and 
in pneumonic whole lungs there was a significant increase in the lungs of mice 
previously exposed to pneumococcus compared to saline-treated controls after 
24 hours of Sp3 infection (Figure 20). While these data are preliminary due to the 
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sample size, they suggest not only that B cell-related gene signatures are robust 
but also that there is perhaps lung-localized antibody synthesis that could 
synergize with cell-mediated anti-pneumococcal responses for rapid bacterial 
clearance.  
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Figure 19: B cell-related gene signatures are highly enriched in pneumonic 
lungs previously exposed to pneumococci. 
 
Genes from the RNA sequencing analysis were selected by a fold change of ≥ 
2.5 and sorted by the highest read numbers in the Het Imm sample. There were 
165 total genes with a read number of at least 50; the top 25 are displayed here 
(n= 1). 
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Figure 20: CXCL13 protein is elevated in pneumonic mouse lungs that were 
previously infected with pneumococcus. 
 
C57BL/6 mice were infected i.n. with Sp19F, Sp35B, and Sp23A or saline. After 
4 weeks they were challenged with 1 x 106 CFU Sp3 via i.t. instillation. Lungs 
were harvested after 24h of pneumonia. CXCL13 protein concentrations were 
measured in whole lung homogenates by ELISA (0h samples had no Sp3 
infection). Data are expressed as pg/lung and bars represent means with SEM 
(n= 10-11). Significance was assessed by 2-way ANOVA followed by Tukey’s 
post hoc test. *p < 0.05 for significant differences between the specified groups. 
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4.2 Previous respiratory exposures to pneumococci provide systemic protection 
against heterotypic pneumococcal infection  
Both human epidemiological and animal experimental data have 
demonstrated that anti-polysaccharide capsular antibodies can provide effective 
serotype-specific protection against invasive pneumococcal infection (Cohen et 
al., 2011; Yildirim et al., 2015). More recently antibodies that bind to common 
pneumococcal cell wall components have been of interest due to their broad 
serotype-binding potential. An experimental model of nasopharyngeal 
pneumococcal colonization in humans demonstrated an increase in serum IgG 
that was specific for certain pneumococcal cell wall components (McCool et al., 
2003). In addition, mice that were colonized with pneumococcus developed 
circulating anti-protein antibodies and were protected from a homotypic 
pneumococcal lung infection (Wilson et al., 2015). With these data in mind, we 
sought to evaluate the protective potential of naturally acquired anti-
pneumococcal antibodies that were not polysaccharide capsule-specific in the 
model of heterotypic immunity described above. Mice subjected to serial 
respiratory exposures (i.n.) with different pneumococci that were previously 
shown to be protected against subsequent unrelated pneumococcal pneumonia, 
along with saline-treated controls were challenged with a systemic Sp3 infection 
via intraperitoneal injection (i.p.) (Figure 21A). After 24 hours, mice from both 
groups were sacrificed and blood CFU counts were determined as a measure of 
systemic protection. Heterotypic mice generated via i.n. exposures to 
  
112 
pneumococci showed limited systemic growth and clearance of Sp3, which they 
had not previously been exposed to, while mice treated with saline displayed 
uncontrolled, multi-log growth (Figure 21A). These data confirm that in a model of 
naturally-acquired respiratory pneumococcal infections the animals are also 
protected against systemic, invasive infection with unrelated pneumococci 
conceivably through the action of circulating, heterotypic antibodies. The 
presence of heterotypic antibodies in the plasma of protected mice, but not in 
susceptible mice, was established using a whole-cell pneumococcal ELISA. 
Plasma isolated from pneumonic heterotypic and saline-treated mice was 
evaluated for the ability of IgG to bind to the surface of both Sp19F (a previously-
encountered serotype) and Sp3 (the challenging serotype) (Figure 21B-D). As 
expected, the plasma from protected mice contained IgG that reacted with the 
surface of Sp19F (Figure18B); there was likely a combination of anti-PC 
antibodies and other antibodies that targeted pneumococcal cell wall 
components that developed following the resolution of the previous infections. 
We observed Sp3-reactive, non-capsular polysaccharide IgG in the plasma of 
pneumonic, protected mice as well as in non-pneumonic mice that were 
previously exposed to pneumococci (Figure 21C-D). Because the assay utilized 
whole cell pneumococci to capture antibodies from mouse plasma and not pre-
determined concentrations of pneumococcal proteins for example, 
concentrations of IgG could not be determined and absorbance values are 
presented instead. These data demonstrate that previous natural exposures to 
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varied pneumococcal serotypes resulted in systemic heterotypic protection. In 
addition, mice that were previously exposed to pneumococci produced IgG 
capable of polysaccharide capsule-independent binding to the previously unseen 
serotype Sp3. 
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Figure 21: Heterotypic immune mice are protected from systemic 
pneumococcal infection. 
 
(A) C57BL/6 mice were infected i.n. with Sp19F, Sp35B, and Sp23A or saline. 
After 4 weeks they were challenged with 3 x 102 CFU Sp3 via i.p. injection. Blood 
was collected after 24h and CFU were determined as a measure of systemic 
bacterial burden (experiment n= 1). Data are expressed as CFU per mL of blood. 
Individual dots represent a single mouse and horizontal lines represent medians. 
The dashed lines indicate the input CFU and limit of detection. Significance was 
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assessed usign a Mann Whitney U test. (B-C) The presence of Sp19F and Sp3-
reactive IgG from the plasma of Het Imm and saline control mice determined by 
whole-cell pneumococcal ELISA. (D) Sp3-reactive plasma IgG was measured in 
non-pneumonic Het Imm and saline mice. Data are expressed as absorbance 
values at 450 nm and bars represent means with SEM (n= 3-7). Significance was 
assessed using the Student’s t test. *p < 0.05 
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4.3 Plasma components of heterotypic mice are sufficient to protect against 
unrelated pneumococcal pneumonia in naïve mice 
 As previously discussed, type-specific serotherapy was a moderately 
successful, yet non-sustainable treatment for pneumococcal disease prior to the 
widespread use of antibiotics (Podolsky, 2005). In order to determine whether 
circulating naturally-acquired immunity against pneumococcus could protect 
naïve animals against respiratory infection with Sp3, plasma from both protected 
and susceptible mice with pneumonia was collected and filtered. Pooled plasma 
from each group was pre-incubated with Sp3 and then the mixture was instilled 
i.t. into the lungs of naïve mice. After 24 hours of infection, the lungs of the naïve 
mice were collected and CFU analysis was performed. Sp3 growth was 
unrestricted in naïve lungs that received plasma from saline donors whereas in 
naïve lungs that received plasma from protected mice, Sp3 growth was not only 
inhibited but multi-log clearance was achieved in most mice (Figure 22). We can 
conclude from these results that the plasma contents from protected mice are 
sufficient to provide heterotypic protection against pneumococcal pneumonia in 
naïve lungs when transferred. 
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Figure 22: Het Imm plasma is sufficient to protect against unrelated 
pneumococcal pneumonia in naïve mice when transferred. 
 
Plasma from pneumonic Het Imm and saline control mice was collected and 
transferred with 5 x 104 CFU Sp3 into the lungs of naïve mice. After 24h, lung 
bacterial burden was determined (experiment n= 1). Data are expressed as CFU 
per lung. Individual dots represent a single mouse and horizontal lines represent 
medians. The dashed line indicates the input CFU. Significance was assessed 
using a Mann Whitney U test. *p < 0.05 
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4.4 B cells are required for optimal heterotypic lung protection  
 Previous studies that have investigated both homologous and 
heterologous recall responses during lung infection due to S. pneumoniae and K. 
pneumonia, respectively, have demonstrated differential requirements of 
antibodies for protective responses that defend the respiratory system (Chen et 
al., 2011; Wilson et al., 2015). In order to determine whether antibodies are 
required for naturally-acquired heterotypic lung protection, B-cell deficient (µMT) 
mice were exposed to 2 doses of Sp19F or saline and then challenged with Sp3 
pneumonia as in the model described above (Kitamura et al., 1991). After 24 
hours, CFU analysis on whole lungs was performed as a measure of heterotypic 
lung protection. Compared to saline treated controls, the lungs of µMT mice 
previously exposed to pneumococci contained significantly less Sp3 (Figure 
23A). This indicated that despite the absence of mature B cells, µMT mice were 
still able to generate heterotypic memory that provided a small yet significant 
amount of protection that was presumably T cell-mediated. In addition to the cell-
mediated responses discussed in chapter 3, pneumococcus-elicited humoral 
responses also significantly contributed to heterotypic lung protection as 
evidenced by the increased CFU in µMT lungs compared to C57BL/6 lungs 
(Figure 23B). Sp3 grew equally well in the naïve lungs of both C57BL/6 and µMT 
mice (Figure 23 C). The degree of heterotypic lung protection displayed by 
previously-exposed µMT mice appeared to be highly variable, with some mice 
near saline control bacteria levels while others possessed close to optimal 
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heterotypic protection (Figure 23 A-B). Previous data demonstrated the 
importance of CD4+ IL-17A-producing cells for optimal pneumococcus-elicited 
heterotypic lung protection (Figure 10A). We therefore hypothesized that the 
protection variability observed in heterotypic µMT mice may be due to differential 
IL-17A protein expression. That is, do µMT mice that express more IL-17A 
following the resolution of pneumococcal infections more effectively clear Sp3 
from their lungs upon challenge? Following an Sp3 pneumonia challenge, 
heterotypic B cell-deficient lungs contained significantly more IL-17A protein than 
their saline-treated counterparts but we observed no correlation to Sp3 lung CFU 
(Figure 24A-B). Altogether, these results emphasize not only the requirement of 
humoral immunity for systemic protection, but also for maximum heterotypic lung 
protection generated through the resolution of repeated pneumococcal 
exposures. Naturally-acquired heterotypic protection against pneumococcal 
pneumonia does not appear to rely solely on cell-mediated or humoral protection, 
but rather on a combination of the two working together to clear the infection and 
return the lung to homeostasis. 
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Figure 23: B cells are required for optimal heterotypic lung protection.  
 
(A-C) C57BL/6 or B cell-deficient µMT mice were infected i.t. with Sp19F (twice, 
1 week apart) or saline and challenged 4 weeks later with 1 x 106  CFU i.t.Sp3. 
Lungs were harvested after 24h of pneumonia and lung bacterial burden was 
determined. Data are expressed as CFU per lung. Individual dots represent a 
single mouse and horizontal lines represent medians. The dashed line indicates 
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the input CFU. Significance was assessed using a Mann-Whitney U test. *p < 
0.05 
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Figure 24: IL-17A protein levels do not correlate with the degree of 
heterotypic lung protection in B cell-deficient mice. 
 
B cell-deficient µMT mice were infected i.t. with Sp19F (twice, 1 week apart) or 
saline and challenged 4 weeks later with 1 x 106 i.t. Sp3 CFU. Lungs were 
harvested after 24h of pneumonia. (A) IL-17A protein concentrations were 
measured in whole lung homogenates by ELISA. Data are expressed as pg/lung 
and bars represent means with SEM (n= 15-23). Significance was assessed 
using the Student’s t test. *p < 0.05 (B) IL-17A protein levels in µMT Het Imm 
lungs were graphed with the matched CFU per lung (Sp3) and the correlation 
was determined using a linear regression analysis. r2 = 0.0001561 
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CHAPTER FIVE: DISCUSSION 
Cell-mediated immunity in the lung  
 The novel model presented here demonstrates that respiratory infections 
with pneumococcus establish heterotypic immune protection against 
pneumococcal pneumonia. We sought to mimic the naturally acquired immune 
protection that is afforded most young, healthy adults, but which wanes due to 
aging and co-morbidities such as smoking, alcohol abuse, and chronic disease 
(Baik et al., 2000; de Roux et al., 2006; Torres et al., 2013). Incorporating this 
model of naturally acquired heterotypic immune protection against pneumonia 
with other mouse models of aging and co-morbidity will facilitate the investigation 
of mechanisms that may provide new insights into the development of 
pneumonia susceptibility, which is common but poorly understood. In this study it 
was our goal to investigate the respiratory immune mechanisms that protect 
against pneumococcal infection, but the model could also be adapted to study 
other common bacterial and viral respiratory pathobionts.  
 The results presented in this body of work suggest that lung TRM cells that 
remain in the lung following the resolution of pneumococcal infections prevent 
subsequent pneumococcal pneumonia. The actions of anti-pneumococcal TRM 
cells likely synergize with other known mechanisms of protection such as central 
memory CD4+ T cells and anti-pneumococcal antibodies as presented in chapter 
4. The field of tissue resident memory is rapidly expanding. It has become 
increasingly clear that following a localized infection with influenza or herpes 
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simplex virus (HSV) that both CD4+ and CD8+ memory T cells are found in the 
lungs and skin, respectively, and upon re-exposure can initiate local recall 
responses (Clark, 2015; Purwar et al., 2011; Turner et al., 2014). Based on work 
from Teijaro et al. that modeled pulmonary influenza infection in mice, we 
identified CD4+ TRM cells as CD11a
hiCD69+CD44hiCD62Llo (Teijaro et al., 2011). 
We observed a prominent population of TRM cells (17% of CD4
+ T cells) based on 
these markers in the lungs of mice that had resolved previous pneumococcal 
infections, while there were very few (<5% of CD4+ T cells) in the lungs of naïve 
mice. The mice that were used all experiments were housed in specific 
pathogen-free facilities, not germ-free, so it is intriguing that we found so few TRM 
cells as the mice were likely exposed to microbes that were not excluded from 
the facility. One explanation could be that while the mice were potentially 
exposed to other microbes, this did not result in an overt inflammatory response 
and therefore generated few if any lung TRM cells. Studies of both human and 
mouse lungs have identified influenza-specific TRM cells, but the data presented 
here are the first evidence of lung TRM cells that are specific to any of the 
bacterial causes of pneumonia (Purwar et al., 2011; Teijaro et al., 2011). Most 
respiratory infections are caused by pathobionts, or potentially pathogenic 
symbionts, and perhaps by the time we reach adulthood, due to immunological 
exposures, we have developed an array of lung TRM cells that may provide 
protection against the microbes that most commonly cause pneumonia 
(Robinson, 2004).  
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 The localization of TRM cells at the anatomical site of a possible reinfection 
is a fundamental aspect of tissue-resident memory and rapid recall responses, 
but the question of how static these cells are within a complex organ remains 
unanswered. One study of a localized skin infection in mice with vaccinia virus 
demonstrated that a population of CD8+, non-circulating TRM cells resided not 
only at the initial site of infection, but also distributed throughout the entire 
surface of the skin (Jiang et al., 2012). Another study found that memory CD8+ 
cells preferentially persisted in the epidermis, at the site of prior infection, in a 
mouse model of cutaneous herpes simplex virus-1 (HSV) infection (Zaid et al., 
2014). While they found that these TRM cells do migrate slightly in a random 
fashion at a very slow rate, they are relatively fixed within a few millimeters of the 
site of initial infection (Zaid et al., 2014). The differences in TRM distribution 
between these two studies could be due to the different courses of infection of 
the two different viruses used. Additionally, in the lungs of mice that had resolved 
an influenza infection, CD4+ lung TRM cells were observed in clusters surrounding 
airways, near pulmonary vessels (Turner et al., 2014). To our knowledge, we are 
the first to show that the localization of lung TRM cells has an impact on the 
outcome of reinfection and memory recall responses. After 24 hours of Sp3 
pneumonia, it was clear that Het Imm mice that were challenged in their 
contralateral right lobes were unable to control the infection and displayed very 
little heterotypic protection. Conversely, Het Imm mice that were challenged in 
their ipsilateral left lobe, at the site of previous pneumococcal infections, 
  
126 
displayed significant protection against the heterotypic pneumococcal challenge. 
This observed difference in protection was not due to the anatomical differences 
between the left and right lobes as Sp3 grew equally well in both sides of the 
lung in naïve mice. Systemic mechanisms of protection, such as central memory 
CD4+ T cells and circulating anti-pneumococcal antibodies, should be equally 
protective for ipsilateral and contralateral lung lobes. While the actions of anti-
pneumococcal TRM cells likely synergize with systemic arms of immunity, the co-
localization of heterotypic lung protection with lung TRM suggests that tissue-
resident immune memory is an essential mechanism of protection that results 
from the resolution of respiratory infection.  
 Due to their potent inflammatory potential, aberrant generation and 
activation of TRM cells could also have deleterious effects. This was first 
demonstrated in fixed drug eruption reactions where skin CD8+ TRM cells 
mediated an allergic response characterized by cutaneous lesions at fixed 
regions of the body upon drug ingestion (Carbone, 2015). TRM cells have also 
been implicated in psoriasis (Park and Kupper, 2015). CD8+ TRM cells extracted 
from resolved human psoriatic skin lesions produced IL-17A upon ex vivo 
stimulation, and isolated epidermal CD4+ T cells produced IL-22, both of which 
play a vital role in disease pathogenesis (Cheuk et al., 2014). Very recently a 
study showed that after exposure to house dust mite allergen, mouse lungs 
contained CD4+ TRM cells that persisted and contributed to airway hyper-
responsiveness (Hondowicz et al., 2016). In these studies IL-2 signaling was 
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required for pathogenic TRM differentiation (Hondowicz et al., 2016). Overall, 
these studies highlight the complexity of tissue-resident memory responses. 
More research is needed to determine how TRM cells develop and what factors 
(ie: chemokines, adhesion molecules, and other survival factors) are required for 
their retention at specific mucosal sites so that we can better understand and 
modulate protective and pathological responses. 
 The effector functions of TRM cells that were generated following the 
resolution of pneumococcal infections may be complex and involve multiple 
parallel protective pathways. When CD4+ TRM cells from the lungs of mice 
previously exposed to pneumococcus were stimulated in an antigen-specific 
manner they produced not only IL-17A but also IFN-γ, IL-2, TNF-α, and IL-22. In 
our stimulation assays these cytokines were not produced simultaneously, most 
cells were single cytokine-producers and did not appear to be polyfunctional. IL-
17A has been shown in many circumstances to be protective during both 
colonization and infection with pneumococcus through the induction of neutrophil 
recruitment (Malley et al., 2006; Wilson et al., 2015). A study published in 2011 
demonstrated that intranasal vaccination with killed Klebsiella pneumoniae 
provided serotype-independent immunity against a heterologous respiratory 
challenge that was dependent on IL-17A-producing CD4+ T cells (Chen et al., 
2011). More recently, it was demonstrated that IL-17-producing memory cells 
were required for serotype-independent protection against pneumococcal 
pneumonia (Wang et al., 2016). 
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In addition to T helper cells, there are also innate sources of IL-17 such as 
gamma-delta (γδ) T cells and group 3 innate lymphoid cells (ILC3). In the 
Klebsiella vaccination study mentioned above, γδ T cells were the main source of 
lung IL-17 during a primary infection, but following vaccination and subsequent 
Klebsiella pneumonia, CD4+ T cells were the dominant source of IL-17 (Chen et 
al., 2011). Another study found that ILC3 cells in the lung were required for IL-17-
mediated clearance of Klebsiella pneumoniae, again during a primary lung 
infection (Xiong et al., 2016). In the context of pneumococcal pneumonia, lung 
ILC3 cells have also been shown to produce IL-17 during a primary infection 
(Van Maele et al., 2014). While we cannot at this time rule out the possibility that 
there are other cellular sources of IL-17 during heterotypic lung protection 
against pneumococcus, our CD4 depletion data suggest that CD4+ T cells are 
the major source of this cytokine.  
IFN-γ stimulation of macrophages induces antimicrobial programs and 
enhances antigen processing and presentation (Schroder et al., 2004). In 
addition, IFN-γ has been shown to facilitate bacterial clearance through the 
augmentation of neutrophil effector function during pneumococcal pneumonia 
(Yamada et al., 2011). IL-22 has been shown to regulate the production of 
antimicrobial peptides by the airway epithelium during gram negative pneumonia 
(Aujla et al., 2008; Aujla et al., 2007). TNF-α signaling during pneumococcal 
pneumonia induces NF-κB nuclear translocation, which drives neutrophil 
recruitment to the infected airspaces (Jones et al., 2005). IL-2 is an important 
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cytokine for T cell proliferation, homeostasis, and differentiation (Boyman and 
Sprent, 2012). The potential role of IL-2 is complex, however, as it has been 
shown in vitro to inhibit the development of the Th17 lineage and reduce IL-17 
production (Laurence et al., 2007). It is possible that the effect of IL-2 on IL-17-
producing cells is context dependent in vivo. Additionally, if one function of IL-2 is 
to dampen Th17 responses, it may serve as a mechanism to control 
inflammation. A shared downstream mechanism for many from this group of 
inflammatory modulators involves the acceleration of neutrophil recruitment and 
amplification of phagocyte function. This redundancy during heterotypic lung 
protection may prevent bacteria from easily developing resistance against these 
important immune mechanisms. 
 
B cell contributions to lung host defense 
 While the data presented in chapter 4 do not yet represent a complete 
story of B cell and antibody contributions to heterotypic lung defense, we have a 
foundation that will direct future studies. Experiments performed in mice that 
were previously exposed to pneumococcus that lacked either CD4+ cells or B 
cells resulted in an intermediate heterotypic protection, not completely lacking as 
in naïve mice, but also not as good as wild-type protected C57BL/6 mice. These 
data suggest that naturally acquired heterotypic lung protection involves a 
collaboration between cell-mediated and humoral immunity. The heterotypic 
protection observed in B cell-deficient mice was also highly variable, and this 
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variability did not correlate with the amount of IL-17A protein present in the lungs. 
This does not mean that IL-17A signaling is not important during heterotypic 
protection, rather that protection likely involves a combination of mechanisms as 
discussed above and does not simply depend on IL-17A alone. Models of 
secondary recall responses to S. pneumoniae and K. pneumoniae have 
demonstrated differential requirements for B cells and antibodies during 
protective responses. Antibody production was not required in airway vaccination 
models of both S. pneumoniae and K. pneumoniae for protection against 
nasopharyngeal colonization and pneumonia challenge, respectively (Chen et al., 
2011; Malley et al., 2005). In both cases, IL-17A-secreting CD4+ T cells were 
required for protection (Chen et al., 2011; Malley et al., 2005). However, when a 
pneumococcal whole-cell immunization was given by subcutaneous injection it 
generated a significant anti-pneumococcal antibody response that was required 
for protection in an aspiration-sepsis challenge model, but CD4+ cells were not 
required (Lu et al., 2010a). Additionally, both cellular and humoral responses 
were required for protection against a homologous pneumococcal pneumonia 
following nasopharyngeal colonization (Wilson et al., 2015). Altogether these 
studies and our own suggest that the primary mechanism of protection against 
pneumococcal disease may depend on the location of the infection, and that an 
ideal vaccine would stimulate both arms of adaptive immunity. 
 Perhaps not surprisingly, naturally-acquired heterotypic protection against 
pneumococcus included systemic anti-pneumococcal antibodies. A portion of this 
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systemic response consisted of heterotypic IgGs that were capable of reacting 
with the surface of the highly encapsulated serotype 3 pneumococcus. We do not 
know the antigen specificity of the heterotypic IgGs, but we presume that it is a 
mixed pool with reactivity to multiple antigens common to the species, some of 
which may include pneumolysin, PspA, PspC, and PsaA (Malley et al., 2001). 
The plasma components of mice that were previously exposed to pneumococcus 
were also protective when transferred to the lungs of naïve mice along with a 
virulent heterologous pneumococcus. Heterotypic anti-pneumococcal IgG is 
presumably the protective component of plasma, but additional experiments will 
confirm this assumption. Plasma transfer experiments could be performed with 
normal Het Imm plasma and also with IgG-depleted Het Imm plasma to 
determine if the lack of IgG results in a loss of protection in naïve lungs. 
 The results of the genome-wide RNA sequencing analysis of pneumonic 
heterotypic and naïve lungs have inspired new lines of thought and investigation. 
It was intriguing that the highest transcript signals in Het Imm lungs were related 
to immunoglobulin production and B cell trafficking. These results lead us to 
speculate that there might be lung-localized production of anti-pneumococcal 
antibodies, and possibly a tissue- resident memory B cell population. Upon 
microscopic examination of H&E-stained Het Imm lungs we did not observe 
obvious iBALT formation, but the strong RNA signal and whole lung increase in 
CXCL13 reinvigorated the search for possible organized lymphoid structures or 
clusters that are not discernable in H&E sections. A study published in 2013 
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demonstrated that both CXCL12 and CXCL13 were important for the formation of 
B cell follicles in induced lung lymphoid tissue. Some pathogens induced both 
chemokines following a pulmonary infection, while others induced only one, as is 
the case for the poxvirus modified vaccinia virus Ankara (MVA) and 
Pseudomonas aeruginosa, respectively (Fleige et al., 2014). Interestingly, IL-17 
was responsible for the production of CXCL12 from lung stromal cells during P. 
aeruginosa infection (Fleige et al., 2014). Future studies will include 
immunofluorescence staining of Het Imm and naïve lung sections at multiple time 
points over the course of the protective recall response in order to look for 
lymphocyte aggregates. Targets will include B and T cell surface markers in 
addition to different immunoglobulin isotypes (IgM, IgG, and IgA) as well as the 
germinal center marker GL7 (Moyron-Quiroz et al., 2004). In addition, the 
question of whether there are lung-resident memory B cells that differentiate into 
plasma cells upon secondary pneumococcal challenge remains unanswered. It is 
also possible that pneumococcus-specific memory B cells that reside in 
secondary lymphoid tissues are activated and differentiate before migrating to 
the lungs during a pneumonia challenge. One group found that after the 
resolution of a primary influenza infection, a population of memory B cells 
persisted in the lungs for more than 5 months, and following reinfection 
differentiated into antibody-secreting plasma cells (Onodera et al., 2012). A 
fraction of these virus-binding memory B cells expressed the splenic memory B 
cell markers CD38, CD73, CD80, and CD273 in addition to CD69 and CXCR3. 
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Both CD69 and CXCR3 have been shown to be important for T cell migration 
and retention in the lungs (Onodera et al., 2012). The first experiments will 
determine whether the lungs of mice previously exposed to pneumococcus 
contain a resident population of memory B cells using some of the cell surface 
markers mentioned above. If we do observe a lung-resident memory B cell 
population, heterotypic mice could be treated with the immune modulating drug 
FTY-720 to prevent lymphocyte egress from the lymph nodes prior to pneumonia 
challenge. We could then evaluate the in situ differentiation of plasma cells over 
time using flow cytometry (Matloubian et al., 2004). Additionally, memory B cells 
could be isolated from Het Imm lungs and stimulated with pneumococcus in 
order to evaluate antigen-specific antibody production (IgG, IgA, and IgM) using 
Enzyme-linked ImmunoSpot (ELISPOT) analysis.  
 
Future Directions 
 A major question that still remains is whether human lungs contain TRM 
cells that respond to different pneumococcal serotypes, and if so what are the 
main effector functions? It would be possible to obtain human lung tissue from 
surgical resections here at BUMC. We could then isolate resident memory cell 
populations, stimulate them with killed pneumococcal serotypes, and analyze  
their proliferation and effector responses (cytokine, antibodies etc.). If we were 
able to obtain tissue from a range of ages we could begin to investigate the 
dynamics of TRM over time. It is well established that elderly adults have 
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increased susceptibility to community-acquired pneumonia with various potential 
explanations including the presence of comorbidities and decline in immune 
function (Marrie, 2000). A loss of naturally-acquired lung resident memory, either 
cell number or function, may contribute to the increase in susceptibility to 
pneumococcal pneumonia as we age. It would be interesting to use our model of 
naturally acquired heterotypic immunity to study the longevity of the CD4+ TRM 
cells that are generated after the resolution of pneumococcal infections. If we did 
see that heterotypic protection and/or CD4+ TRM cells wane over time, another 
pneumococcal infection or “boost” could be given to test whether this would 
restore some or all of the protective capacity. 
 Another interesting avenue to pursue would involve investigating the 
factors that are important for the establishment and maintenance of TRM in the 
lung. CXCL12 and CXCL13 were mentioned above as potential important 
chemokines for the establishment of B cell follicles, but we don’t yet know what 
chemokines and signals are important for CD4+ T cell TRM establishment, 
especially following bacterial lung infections. Studies using viral lung infection 
models have determined that the collagen-binding integrin VLA-1 is important for 
retaining CD4+ TRM in the lungs (Chiu and Openshaw, 2015). In addition, effector 
T cells in the lungs often express the chemokine receptors CXCR3 and CCR4 
among others (Chiu and Openshaw, 2015). There are also likely environmental 
cues in the lungs that influence the TRM differentiation process. By inhibiting 
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some of these possible integrin and chemokine interactions we could begin to 
learn more about the process of establishing TRM in the lung.  
 The goal of the work presented here was to increase our understanding of 
the naturally acquired immune mechanisms that mediate rapid recall responses 
in the lung. Information about lung resident memory cell populations and their 
potential for compartmentalization, as demonstrated in our model, could help 
shape the future design of pneumococcal vaccines. In addition, knowledge of 
these immune mechanisms may help the medical field modulate both the 
protective and pathological responses that are mediated by lung resident 
memory cells in disease states. 
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